{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T06:19:01Z","timestamp":1794464341684,"version":"4.9.1"},"reference-count":417,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Biofilms Microbiomes"],"DOI":"10.1038\/s41522-025-00786-8","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T13:18:30Z","timestamp":1753449510000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":173,"title":["Gut microbiota shapes cancer immunotherapy responses"],"prefix":"10.1038","volume":"11","author":[{"given":"Wanting","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"786_CR1","first-page":"8","volume":"15","author":"J Lederberg","year":"2001","unstructured":"Lederberg, J. & McCray, A. T. \u2018Ome Sweet\u2019 Omics\u2014a genealogical treasury of words. Scientist 15, 8\u20138 (2001).","journal-title":"Scientist"},{"key":"786_CR2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.cell.2016.01.013","volume":"164","author":"R Sender","year":"2016","unstructured":"Sender, R., Fuchs, S. & Milo, R. Are we really vastly outnumbered? revisiting the ratio of bacterial to host cells in humans. Cell 164, 337\u2013340 (2016).","journal-title":"Cell"},{"key":"786_CR3","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nm.4517","volume":"24","author":"JA Gilbert","year":"2018","unstructured":"Gilbert, J. A. et al. Current understanding of the human microbiome. Nat. Med. 24, 392\u2013400 (2018).","journal-title":"Nat. Med."},{"key":"786_CR4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.chom.2019.08.011","volume":"26","author":"K Martinez-Guryn","year":"2019","unstructured":"Martinez-Guryn, K., Leone, V. & Chang, E. B. Regional diversity of the gastrointestinal microbiome. Cell Host Microbe 26, 314\u2013324 (2019).","journal-title":"Cell Host Microbe"},{"key":"786_CR5","doi-asserted-by":"publisher","first-page":"e1002533","DOI":"10.1371\/journal.pbio.1002533","volume":"14","author":"R Sender","year":"2016","unstructured":"Sender, R., Fuchs, S. & Milo, R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 14, e1002533 (2016).","journal-title":"PLoS Biol."},{"key":"786_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature11551","volume":"489","author":"CL Maynard","year":"2012","unstructured":"Maynard, C. L., Elson, C. O. & Hatton, R. D. Reciprocal interactions of the intestinal microbiota and immune system. Nature 489, 231\u2013241 (2012).","journal-title":"Nature"},{"key":"786_CR7","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.immuni.2017.04.008","volume":"46","author":"Y Belkaid","year":"2017","unstructured":"Belkaid, Y. & Harrison, O. J. Homeostatic Immunity and the Microbiota. Immunity 46, 562\u2013576 (2017).","journal-title":"Immunity"},{"key":"786_CR8","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/j.immuni.2021.05.017","volume":"54","author":"BE Jugder","year":"2021","unstructured":"Jugder, B. E., Kamareddine, L. & Watnick, P. I. Microbiota-derived acetate activates intestinal innate immunity via the Tip60 histone acetyltransferase complex. Immunity 54, 1683\u20131697.e3 (2021).","journal-title":"Immunity"},{"key":"786_CR9","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41422-020-0332-7","volume":"30","author":"D Zheng","year":"2020","unstructured":"Zheng, D., Liwinski, T. & Elinav, E. Interaction between microbiota and immunity in health and disease. Cell Res. 30, 492\u2013506 (2020).","journal-title":"Cell Res."},{"key":"786_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.171","volume":"3","author":"K Lin","year":"2022","unstructured":"Lin, K., Zhu, L. & Yang, L. Gut and obesity\/metabolic disease: Focus on microbiota metabolites. MedComm 3, e171 (2022).","journal-title":"MedComm"},{"key":"786_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-019-0704-8","volume":"7","author":"K Oliphant","year":"2019","unstructured":"Oliphant, K. & Allen-Vercoe, E. Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health. Microbiome 7, 91 (2019).","journal-title":"Microbiome"},{"key":"786_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/jambio\/lxad032","volume":"134","author":"Y Chen","year":"2023","unstructured":"Chen, Y., Wang, Z., Chen, X., Chao, G. & Zhang, S. The role of gut microbiota and metabolites in regulating the immune response in drug-induced enteritis. J. Appl. Microbiol. 134, lxad032 (2023).","journal-title":"J. Appl. Microbiol."},{"key":"786_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.703218","volume":"9","author":"A Visekruna","year":"2021","unstructured":"Visekruna, A. & Luu, M. The role of short-chain fatty acids and bile acids in intestinal and liver function, inflammation, and carcinogenesis. Front. Cell Dev. Biol. 9, 703218 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"786_CR14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1146\/annurev-immunol-093019-112348","volume":"39","author":"E Ansaldo","year":"2021","unstructured":"Ansaldo, E., Farley, T. K. & Belkaid, Y. Control of immunity by the microbiota. Annu. Rev. Immunol. 39, 449\u2013479 (2021).","journal-title":"Annu. Rev. Immunol."},{"key":"786_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1146\/annurev-immunol-051116-052133","volume":"35","author":"A Dzutsev","year":"2017","unstructured":"Dzutsev, A. et al. Microbes and cancer. Annu. Rev. Immunol. 35, 199\u2013228 (2017).","journal-title":"Annu. Rev. Immunol."},{"key":"786_CR16","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. & Zhang, Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol. Immunol. 17, 807\u2013821 (2020).","journal-title":"Cell Mol. Immunol."},{"key":"786_CR17","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"786_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13045-020-00862-w","volume":"13","author":"C Pan","year":"2020","unstructured":"Pan, C. et al. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. J. Hematol. Oncol. 13, 29 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"786_CR19","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/iid3.511","volume":"9","author":"M Wang","year":"2021","unstructured":"Wang, M. et al. Clinical observation of the efficacy of PD-1\/PD-L1 inhibitors in the treatment of patients with advanced solid tumors. Immun. Inflamm. Dis. 9, 1584\u20131595 (2021).","journal-title":"Immun. Inflamm. Dis."},{"key":"786_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde, P. S. & Chen, D. S. Top 10 challenges in cancer immunotherapy. Immunity 52, 17\u201335 (2020).","journal-title":"Immunity"},{"key":"786_CR21","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.ccell.2021.08.006","volume":"39","author":"N Cullin","year":"2021","unstructured":"Cullin, N., Antunes, C. A., Straussman, R., Stein-Thoeringer, C. K. & Elinav, E. Microbiome and cancer. Cancer Cell 39, 1317\u20131341 (2021).","journal-title":"Cancer Cell"},{"key":"786_CR22","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1038\/s41590-021-01082-1","volume":"22","author":"Z Fehervari","year":"2021","unstructured":"Fehervari, Z. Microbiota shape tumor immunity. Nat. Immunol. 22, 1469 (2021).","journal-title":"Nat. Immunol."},{"key":"786_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","volume":"578","author":"Consortium I. T. P.-C. A. O. W. G.","year":"2020","unstructured":"Consortium I. T. P.-C. A. O. W. G. Pan-cancer analysis of whole genomes. Nature 578, 82\u201393 (2020).","journal-title":"Nature"},{"key":"786_CR24","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1158\/2159-8290.CD-21-0999","volume":"12","author":"S Yonekura","year":"2022","unstructured":"Yonekura, S. et al. Cancer Induces a Stress Ileopathy Depending on \u03b2-Adrenergic Receptors and Promoting Dysbiosis that Contributes to Carcinogenesis. Cancer Discov. 12, 1128\u20131151 (2022).","journal-title":"Cancer Discov."},{"key":"786_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91\u201397 (2018).","journal-title":"Science"},{"key":"786_CR26","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1126\/science.abb5920","volume":"371","author":"EN Baruch","year":"2021","unstructured":"Baruch, E. N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371, 602\u2013609 (2021).","journal-title":"Science"},{"key":"786_CR27","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41591-022-01694-6","volume":"28","author":"N Dizman","year":"2022","unstructured":"Dizman, N. et al. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat. Med. 28, 704\u2013712 (2022).","journal-title":"Nat. Med."},{"key":"786_CR28","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1126\/science.aaz7015","volume":"374","author":"CN Spencer","year":"2021","unstructured":"Spencer, C. N. et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science 374, 1632\u20131640 (2021).","journal-title":"Science"},{"key":"786_CR29","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.7150\/thno.91700","volume":"14","author":"Q Liu","year":"2024","unstructured":"Liu, Q. et al. Role of the gut microbiota in tumorigenesis and treatment. Theranostics 14, 2304\u20132328 (2024).","journal-title":"Theranostics"},{"key":"786_CR30","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41577-023-00951-0","volume":"24","author":"SJ Blake","year":"2024","unstructured":"Blake, S. J., Wolf, Y., Boursi, B. & Lynn, D. J. Role of the microbiota in response to and recovery from cancer therapy. Nat. Rev. Immunol. 24, 308\u2013325 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"786_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1269054","volume":"14","author":"M Wang","year":"2023","unstructured":"Wang, M., Yu, F. & Li, P. Intratumor microbiota in cancer pathogenesis and immunity: from mechanisms of action to therapeutic opportunities. Front. Immunol. 14, 1269054 (2023).","journal-title":"Front. Immunol."},{"key":"786_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01134-z","volume":"21","author":"H Ji","year":"2023","unstructured":"Ji, H. et al. Intratumoural microbiota: from theory to clinical application. Cell Commun. Signal 21, 164 (2023).","journal-title":"Cell Commun. Signal"},{"key":"786_CR33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41392-023-01693-0","volume":"9","author":"Y Cao","year":"2024","unstructured":"Cao, Y. et al. Intratumoural microbiota: a new frontier in cancer development and therapy. Signal Transduct. Target Ther. 9, 15 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"786_CR34","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","volume":"21","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 21, 44\u201359 (2020).","journal-title":"Lancet Oncol."},{"key":"786_CR35","doi-asserted-by":"publisher","first-page":"9024","DOI":"10.1200\/JCO.2023.41.16_suppl.9024","volume":"41","author":"K He","year":"2023","unstructured":"He, K., et al. Safety and clinical activity of target-preserving anti-CTLA-4 antibody ONC-392 as monotherapy in NSCLC patients who progressed on PD(L)1-targeted immunotherapy. J. Clin. Oncol. 41, 9024\u20139024 (2023).","journal-title":"J. Clin. Oncol."},{"key":"786_CR36","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","volume":"16","author":"P Zhang","year":"2023","unstructured":"Zhang, P., Zhang, G. & Wan, X. Challenges and new technologies in adoptive cell therapy. J. Hematol. Oncol. 16, 97 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"786_CR37","first-page":"514","volume":"42","author":"CL Ventola","year":"2017","unstructured":"Ventola, C. L. Cancer immunotherapy, Part 3: challenges and future trends. P T 42, 514\u2013521 (2017).","journal-title":"P T"},{"key":"786_CR38","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819\u2013829 (2016).","journal-title":"N. Engl. J. Med."},{"key":"786_CR39","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","volume":"8","author":"M Sade-Feldman","year":"2017","unstructured":"Sade-Feldman, M. et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 8, 1136\u20131136 (2017).","journal-title":"Nat. Commun."},{"key":"786_CR40","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219\u20131226 (2018).","journal-title":"Cancer Discov."},{"key":"786_CR41","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221096219","volume":"14","author":"AM Starzer","year":"2022","unstructured":"Starzer, A. M., Preusser, M. & Berghoff, A. S. Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle. Ther. Adv. Med Oncol. 14, 17588359221096219 (2022).","journal-title":"Ther. Adv. Med Oncol."},{"key":"786_CR42","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543\u2013550 (2014).","journal-title":"Nature"},{"key":"786_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers, Z. R. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9, 34 (2017).","journal-title":"Genome Med."},{"key":"786_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10391","volume":"7","author":"K Dubin","year":"2016","unstructured":"Dubin, K. et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat. Commun. 7, 10391 (2016).","journal-title":"Nat. Commun."},{"key":"786_CR45","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan, V. et al. Gut microbiome modulates response to anti- PD-1 immunotherapy in melanoma patients. Science 359, 97\u2013103 (2018).","journal-title":"Science"},{"key":"786_CR46","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104\u2013108 (2018).","journal-title":"Science"},{"key":"786_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0672-4","volume":"11","author":"BA Peters","year":"2019","unstructured":"Peters, B. A. et al. Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients. Genome Med. 11, 61 (2019).","journal-title":"Genome Med."},{"key":"786_CR48","doi-asserted-by":"publisher","first-page":"847","DOI":"10.21037\/tlcr.2019.10.23","volume":"8","author":"Y Katayama","year":"2019","unstructured":"Katayama, Y. et al. The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer. Transl. Lung Cancer Res. 8, 847\u2013853 (2019).","journal-title":"Transl. Lung Cancer Res."},{"key":"786_CR49","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.jtho.2019.04.007","volume":"14","author":"Y Jin","year":"2019","unstructured":"Jin, Y. et al. The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC. J. Thorac. Oncol. 14, 1378\u20131389 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"786_CR50","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s40425-019-0650-9","volume":"7","author":"Y Zheng","year":"2019","unstructured":"Zheng, Y. et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J. Immunother. Cancer 7, 193 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"786_CR51","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.140940","volume":"5","author":"A Limeta","year":"2020","unstructured":"Limeta, A. et al. Meta-analysis of the gut microbiota in predicting response to cancer immunotherapy in metastatic melanoma. JCI Insight 5, e140940 (2020).","journal-title":"JCI Insight"},{"key":"786_CR52","doi-asserted-by":"publisher","first-page":"8730","DOI":"10.3390\/ijms21228730","volume":"21","author":"P Vernocchi","year":"2020","unstructured":"Vernocchi, P. et al. Network analysis of gut microbiome and metabolome to discover microbiota-linked biomarkers in patients affected by non-small cell lung cancer. Int J. Mol. Sci. 21, 8730 (2020).","journal-title":"Int J. Mol. Sci."},{"key":"786_CR53","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1158\/2326-6066.CIR-19-1014","volume":"8","author":"Z Peng","year":"2020","unstructured":"Peng, Z. et al. The gut microbiome is associated with clinical response to anti-PD-1\/PD-L1 immunotherapy in gastrointestinal cancer. Cancer Immunol. Res. 8, 1251\u20131261 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"786_CR54","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.eururo.2020.07.011","volume":"78","author":"NJ Salgia","year":"2020","unstructured":"Salgia, N. J. et al. Stool microbiome profiling of patients with metastatic renal cell carcinoma receiving anti-PD-1 immune checkpoint inhibitors. Eur. Urol. 78, 498\u2013502 (2020).","journal-title":"Eur. Urol."},{"key":"786_CR55","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","volume":"371","author":"D Davar","year":"2021","unstructured":"Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371, 595\u2013602 (2021).","journal-title":"Science"},{"key":"786_CR56","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1038\/s41591-021-01406-6","volume":"27","author":"MC Andrews","year":"2021","unstructured":"Andrews, M. C. et al. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat. Med. 27, 1432\u20131441 (2021).","journal-title":"Nat. Med."},{"key":"786_CR57","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/ijc.33557","volume":"149","author":"K Takada","year":"2021","unstructured":"Takada, K. et al. Clinical impact of probiotics on the efficacy of anti-PD-1monotherapy in patients with non-small cell lung cancer: a multicenter retrospective survival analysis study with inverse probability of treatment weighting. Int. J. Cancer 149, 473\u2013482 (2021).","journal-title":"Int. J. Cancer"},{"key":"786_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08530-z","volume":"21","author":"J Chau","year":"2021","unstructured":"Chau, J. et al. Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer. BMC Cancer 21, 808 (2021).","journal-title":"BMC Cancer"},{"key":"786_CR59","doi-asserted-by":"publisher","first-page":"e003334","DOI":"10.1136\/jitc-2021-003334","volume":"9","author":"J Mao","year":"2021","unstructured":"Mao, J. et al. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. J. Immunother. Cancer 9, e003334 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"786_CR60","doi-asserted-by":"publisher","first-page":"7340","DOI":"10.3748\/wjg.v27.i42.7340","volume":"27","author":"MW Chung","year":"2021","unstructured":"Chung, M. W. et al. Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients. World J. Gastroenterol. 27, 7340\u20137349 (2021).","journal-title":"World J. Gastroenterol."},{"key":"786_CR61","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1976953","volume":"10","author":"D Yang","year":"2021","unstructured":"Yang, D. et al. Blood microbiota diversity determines response of advanced colorectal cancer to chemotherapy combined with adoptive T cell immunotherapy. Oncoimmunology 10, 1976953 (2021).","journal-title":"Oncoimmunology"},{"key":"786_CR62","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.20892\/j.issn.2095-3941.2020.0450","volume":"18","author":"H Yin","year":"2021","unstructured":"Yin, H. et al. The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms. Cancer Biol. Med. 18, 1040 (2021).","journal-title":"Cancer Biol. Med."},{"key":"786_CR63","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41591-022-01695-5","volume":"28","author":"KA Lee","year":"2022","unstructured":"Lee, K. A. et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nat. Med. 28, 535\u2013544 (2022).","journal-title":"Nat. Med."},{"key":"786_CR64","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41591-022-01698-2","volume":"28","author":"JA McCulloch","year":"2022","unstructured":"McCulloch, J. A. et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat. Med. 28, 545\u2013556 (2022).","journal-title":"Nat. Med."},{"key":"786_CR65","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1038\/s41591-022-01965-2","volume":"28","author":"RC Simpson","year":"2022","unstructured":"Simpson, R. C. et al. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. Nat. Med. 28, 2344\u20132352 (2022).","journal-title":"Nat. Med."},{"key":"786_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01037-7","volume":"14","author":"RC Newsome","year":"2022","unstructured":"Newsome, R. C. et al. Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort. Genome Med. 14, 35 (2022).","journal-title":"Genome Med."},{"key":"786_CR67","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2147\/OTT.S348382","volume":"15","author":"S Chu","year":"2022","unstructured":"Chu, S. et al. Airway Fusobacterium is associated with poor response to immunotherapy in lung cancer. Onco Targets Ther. 15, 201\u2013213 (2022).","journal-title":"Onco Targets Ther."},{"key":"786_CR68","doi-asserted-by":"publisher","first-page":"e004779","DOI":"10.1136\/jitc-2022-004779","volume":"10","author":"PC Lee","year":"2022","unstructured":"Lee, P. C. et al. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J. Immunother. Cancer 10, e004779 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"786_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10004-9","volume":"22","author":"H Che","year":"2022","unstructured":"Che, H. et al. Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors. BMC Cancer 22, 904 (2022).","journal-title":"BMC Cancer"},{"key":"786_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100822","volume":"32","author":"LB Peiffer","year":"2022","unstructured":"Peiffer, L. B. et al. Composition of gastrointestinal microbiota in association with treatment response in individuals with metastatic castrate resistant prostate cancer progressing on enzalutamide and initiating treatment with anti-PD-1 (pembrolizumab). Neoplasia 32, 100822 (2022).","journal-title":"Neoplasia"},{"key":"786_CR71","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41591-022-01702-9","volume":"28","author":"M Smith","year":"2022","unstructured":"Smith, M. et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat. Med. 28, 713\u2013723 (2022).","journal-title":"Nat. Med."},{"key":"786_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32960-3","volume":"13","author":"Y Hu","year":"2022","unstructured":"Hu, Y. et al. CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies. Nat. Commun. 13, 5313 (2022).","journal-title":"Nat. Commun."},{"key":"786_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.953884","volume":"12","author":"L Xu","year":"2022","unstructured":"Xu, L. et al. Genomic and microbial factors affect the prognosis of anti-pd-1 immunotherapy in nasopharyngeal carcinoma. Front. Oncol. 12, 953884 (2022).","journal-title":"Front. Oncol."},{"key":"786_CR74","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/s41591-023-02453-x","volume":"29","author":"B Routy","year":"2023","unstructured":"Routy, B. et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nat. Med. 29, 2121\u20132132 (2023).","journal-title":"Nat. Med."},{"key":"786_CR75","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2204746","volume":"12","author":"D Dora","year":"2023","unstructured":"Dora, D. et al. Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status. Oncoimmunology 12, 2204746 (2023).","journal-title":"Oncoimmunology"},{"key":"786_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-29136-4","volume":"13","author":"Y Haberman","year":"2023","unstructured":"Haberman, Y. et al. Gut microbial signature in lung cancer patients highlights specific taxa as predictors for durable clinical benefit. Sci. Rep. 13, 2007 (2023).","journal-title":"Sci. Rep."},{"key":"786_CR77","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1312","volume":"13","author":"Z Han","year":"2023","unstructured":"Han, Z. et al. The gut microbiome affects response of treatments in HER2-negative advanced gastric cancer. Clin. Transl. Med. 13, e1312 (2023). 2023.","journal-title":"Clin. Transl. Med."},{"key":"786_CR78","doi-asserted-by":"publisher","first-page":"102315","DOI":"10.1016\/j.eclinm.2023.102315","volume":"66","author":"W Zhao","year":"2023","unstructured":"Zhao, W. et al. Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215). EClinicalMedicine 66, 102315 (2023).","journal-title":"EClinicalMedicine"},{"key":"786_CR79","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/s41591-023-02234-6","volume":"29","author":"CK Stein-Thoeringer","year":"2023","unstructured":"Stein-Thoeringer, C. K. et al. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat. Med. 29, 906\u2013916 (2023).","journal-title":"Nat. Med."},{"key":"786_CR80","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41591-024-02803-3","volume":"30","author":"JR Bj\u00f6rk","year":"2024","unstructured":"Bj\u00f6rk, J. R. et al. Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma. Nat. Med. 30, 785\u2013796 (2024).","journal-title":"Nat. Med."},{"key":"786_CR81","doi-asserted-by":"publisher","first-page":"6936","DOI":"10.21037\/jtd-24-1201","volume":"16","author":"L Sun","year":"2024","unstructured":"Sun, L. et al. Gut microbiota and metabolites associated with immunotherapy efficacy in extensive-stage small cell lung cancer: a pilot study. J. Thorac. Dis. 16, 6936\u20136954 (2024).","journal-title":"J. Thorac. Dis."},{"key":"786_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-79339-6","volume":"14","author":"P Sitthideatphaiboon","year":"2024","unstructured":"Sitthideatphaiboon, P. et al. Dietary pattern and the corresponding gut microbiome in response to immunotherapy in Thai patients with advanced non-small cell lung cancer (NSCLC). Sci. Rep. 14, 27791 (2024).","journal-title":"Sci. Rep."},{"key":"786_CR83","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.medj.2024.07.002","volume":"5","author":"Z Yang","year":"2024","unstructured":"Yang, Z. et al. Gut microbiome model predicts response to neoadjuvant immunotherapy plus chemoradiotherapy in rectal cancer. Med 5, 1293\u20131306.e4 (2024).","journal-title":"Med"},{"key":"786_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49842-5","volume":"15","author":"M Zhang","year":"2024","unstructured":"Zhang, M. et al. A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma. Nat. Commun. 15, 7187 (2024).","journal-title":"Nat. Commun."},{"key":"786_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54565-8","volume":"15","author":"SR Rosario","year":"2024","unstructured":"Rosario, S. R. et al. Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer. Nat. Commun. 15, 10609 (2024).","journal-title":"Nat. Commun."},{"key":"786_CR86","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1016\/j.ccell.2024.10.007","volume":"42","author":"D Davar","year":"2024","unstructured":"Davar, D. et al. Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: a prospective phase II trial. Cancer Cell 42, 1898\u20131918.e12 (2024).","journal-title":"Cancer Cell"},{"key":"786_CR87","doi-asserted-by":"crossref","unstructured":"Gao, W. et al. Predictable regulation of gut microbiome in immunotherapeutic efficacy of gastric cancer. Genes Immun. 26, 1\u20138 (2024).","DOI":"10.1038\/s41435-024-00306-2"},{"key":"786_CR88","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/j.chom.2024.10.006","volume":"32","author":"ADG Macandog","year":"2025","unstructured":"Macandog, A. D. G. et al. Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients. Cell Host Microbe 32, 2004\u20132018.e9 (2025).","journal-title":"Cell Host Microbe"},{"key":"786_CR89","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/hed.27917","volume":"47","author":"Z Yu","year":"2025","unstructured":"Yu, Z. et al. Lachnoclostridium intestinal flora is associated with immunotherapy efficacy in nasopharyngeal carcinoma. Head. Neck 47, 269\u2013281 (2025).","journal-title":"Head. Neck"},{"key":"786_CR90","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature12721","volume":"504","author":"Y Furusawa","year":"2013","unstructured":"Furusawa, Y. et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504, 446\u2013450 (2013).","journal-title":"Nature"},{"key":"786_CR91","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1126\/science.1241165","volume":"341","author":"PM Smith","year":"2013","unstructured":"Smith, P. M. et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341, 569\u2013573 (2013).","journal-title":"Science"},{"key":"786_CR92","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1126\/science.1240537","volume":"342","author":"S Viaud","year":"2013","unstructured":"Viaud, S. et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342, 971\u2013976 (2013).","journal-title":"Science"},{"key":"786_CR93","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aac4255","volume":"350","author":"A Sivan","year":"2015","unstructured":"Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350, 1084\u20131089 (2015).","journal-title":"Science"},{"key":"786_CR94","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","volume":"350","author":"M V\u00e9tizou","year":"2015","unstructured":"V\u00e9tizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079\u20131084 (2015).","journal-title":"Science"},{"key":"786_CR95","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1001\/jamaoncol.2019.2785","volume":"5","author":"DJ Pinato","year":"2019","unstructured":"Pinato, D. J. et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 5, 1774\u20131778 (2019).","journal-title":"JAMA Oncol."},{"key":"786_CR96","doi-asserted-by":"publisher","first-page":"e1568812","DOI":"10.1080\/2162402X.2019.1568812","volume":"8","author":"A Elkrief","year":"2019","unstructured":"Elkrief, A. et al. Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. Oncoimmunology 8, e1568812 (2019).","journal-title":"Oncoimmunology"},{"key":"786_CR97","unstructured":"Zhu, X. et al. Interplay between gut microbial communities and metabolites modulates pan-cancer immunotherapy responses. Cell Metab. S1550-4131(24)00495-9 (2025)."},{"key":"786_CR98","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41591-024-02823-z","volume":"30","author":"A Gunjur","year":"2024","unstructured":"Gunjur, A. et al. A gut microbial signature for combination immune checkpoint blockade across cancer types. Nat. Med. 30, 797\u2013809 (2024).","journal-title":"Nat. Med."},{"key":"786_CR99","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200606","volume":"218","author":"AL Byrd","year":"2021","unstructured":"Byrd, A. L. et al. Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers. J. Exp. Med 218, e20200606 (2021).","journal-title":"J. Exp. Med"},{"key":"786_CR100","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1136\/gutjnl-2021-324755","volume":"71","author":"E Kartal","year":"2022","unstructured":"Kartal, E. et al. A faecal microbiota signature with high specificity for pancreatic cancer. Gut 71, 1359\u20131372 (2022).","journal-title":"Gut"},{"key":"786_CR101","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1038\/s41418-021-00784-1","volume":"28","author":"S Terrisse","year":"2021","unstructured":"Terrisse, S. et al. Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. Cell Death Differ. 28, 2778\u20132796 (2021).","journal-title":"Cell Death Differ."},{"key":"786_CR102","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s40487-021-00171-3","volume":"9","author":"D He","year":"2021","unstructured":"He, D. et al. Response to PD-1-based immunotherapy for non- small cell lung cancer altered by gut microbiota. Oncol. Ther. 9, 647\u2013657 (2021).","journal-title":"Oncol. Ther."},{"key":"786_CR103","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","volume":"28","author":"L Derosa","year":"2022","unstructured":"Derosa, L. et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non- small-cell lung cancer. Nat. Med. 28, 315\u2013324 (2022).","journal-title":"Nat. Med."},{"key":"786_CR104","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41586-024-07182-w","volume":"628","author":"M Zepeda-Rivera","year":"2024","unstructured":"Zepeda-Rivera, M. et al. A distinct Fusobacterium nucleatum clade dominates the colorectal cancer niche. Nature 628, 424\u2013432 (2024).","journal-title":"Nature"},{"key":"786_CR105","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf3700","volume":"9","author":"E Baulu","year":"2023","unstructured":"Baulu, E., Gardet, C., Chuvin, N. & Depil, S. TCR-engineered T cell therapy in solid tumors: State of the art and perspectives. Sci. Adv. 9, eadf3700 (2023).","journal-title":"Sci. Adv."},{"key":"786_CR106","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","volume":"42","author":"U Uslu","year":"2024","unstructured":"Uslu, U., Castelli, S. & June, C. H. CAR T cell combination therapies to treat cancer. Cancer Cell 42, 1319\u20131325 (2024).","journal-title":"Cancer Cell"},{"key":"786_CR107","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1172\/JCI32205","volume":"117","author":"CM Paulos","year":"2007","unstructured":"Paulos, C. M. et al. Microbial translocation augments the function of adoptively transferred self\/tumor-specific CD8+ T cells via TLR4 signaling. J. Clin. Invest. 117, 2197\u20132204 (2007).","journal-title":"J. Clin. Invest."},{"key":"786_CR108","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94952","volume":"3","author":"M Uribe-Herranz","year":"2018","unstructured":"Uribe-Herranz, M. et al. Gut microbiota modulates adoptive cell therapy via CD8\u03b1 dendritic cells and IL-12. JCI Insight 3, e94952 (2018).","journal-title":"JCI Insight"},{"key":"786_CR109","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan5931","volume":"360","author":"C Ma","year":"2018","unstructured":"Ma, C. et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science 360, eaan5931 (2018).","journal-title":"Science"},{"key":"786_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-32860-x","volume":"8","author":"M Luu","year":"2018","unstructured":"Luu, M. et al. Regulation of the effector function of CD8+ T cells by gut microbiota-derived metabolite butyrate. Sci. Rep. 8, 14430 (2018).","journal-title":"Sci. Rep."},{"key":"786_CR111","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.cmet.2021.03.002","volume":"33","author":"Y He","year":"2021","unstructured":"He, Y. et al. Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity. Cell Metab. 33, 988\u20131000.e7 (2021).","journal-title":"Cell Metab."},{"key":"786_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24331-1","volume":"12","author":"M Luu","year":"2021","unstructured":"Luu, M. et al. Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer. Nat. Commun. 12, 4077 (2021).","journal-title":"Nat. Commun."},{"key":"786_CR113","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3390\/cancers15030794","volume":"15","author":"S Asokan","year":"2023","unstructured":"Asokan, S., Cullin, N., Stein-Thoeringer, C. K. & Elinav, E. CAR-T cell therapy and the gut microbiota. Cancers (Basel) 15, 794 (2023).","journal-title":"Cancers (Basel)"},{"key":"786_CR114","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1136\/gutjnl-2016-313498","volume":"67","author":"E Cremonesi","year":"2018","unstructured":"Cremonesi, E. et al. Gut microbiota modulate T cell trafficking into human colorectal cancer. Gut 67, 1984\u20131994 (2018).","journal-title":"Gut"},{"key":"786_CR115","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41392-024-02028-3","volume":"9","author":"C Zhu","year":"2024","unstructured":"Zhu, C. et al. Remolding the tumor microenvironment by bacteria augments adoptive T cell therapy in advanced-stage solid tumors. Signal Transduct. Target Ther. 9, 307 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"786_CR116","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","volume":"20","author":"B Pulendran","year":"2021","unstructured":"Pulendran, B., Arunachalam, P. S. & O\u2019Hagan, D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454\u2013475 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"786_CR117","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1586\/14760584.2014.863715","volume":"13","author":"H Shirota","year":"2014","unstructured":"Shirota, H. & Klinman, D. M. Recent progress concerning CpG DNA and its use as a vaccine adjuvant. Expert Rev. Vaccines 13, 299\u2013312 (2014).","journal-title":"Expert Rev. Vaccines"},{"key":"786_CR118","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1158\/2159-8290.CD-21-0425","volume":"11","author":"A Ribas","year":"2021","unstructured":"Ribas, A. et al. Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma. Cancer Discov. 11, 2998\u20133007 (2021).","journal-title":"Cancer Discov."},{"key":"786_CR119","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1158\/0008-5472.CAN-04-4262","volume":"65","author":"C Guiducci","year":"2005","unstructured":"Guiducci, C. et al. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65, 3437\u20133446 (2005).","journal-title":"Cancer Res."},{"key":"786_CR120","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1126\/science.1240527","volume":"342","author":"N Iida","year":"2013","unstructured":"Iida, N. et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342, 967\u2013970 (2013).","journal-title":"Science"},{"key":"786_CR121","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nri.2017.7","volume":"17","author":"M Levy","year":"2017","unstructured":"Levy, M., Kolodziejczyk, A. A., Thaiss, C. A. & Elinav, E. Dysbiosis and the immune system. Nat. Rev. Immunol. 17, 219\u2013232 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"786_CR122","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/86373","volume":"2","author":"M Rescigno","year":"2001","unstructured":"Rescigno, M. et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immunol. 2, 361\u2013367 (2001).","journal-title":"Nat. Immunol."},{"key":"786_CR123","doi-asserted-by":"publisher","DOI":"10.1038\/srep29401","volume":"6","author":"H Deng","year":"2016","unstructured":"Deng, H. et al. A novel strain of Bacteroides fragilis enhances phagocytosis and polarises M1 macrophages. Sci. Rep. 6, 29401 (2016).","journal-title":"Sci. Rep."},{"key":"786_CR124","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.immuni.2014.06.015","volume":"41","author":"D Ramanan","year":"2014","unstructured":"Ramanan, D., Tang, M. S., Bowcutt, R., Loke, P. & Cadwell, K. Bacterial sensor Nod2 prevents inflammation of the small intestine by restricting the expansion of the commensal Bacteroides vulgatus. Immunity 41, 311\u2013324 (2014).","journal-title":"Immunity"},{"key":"786_CR125","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1126\/science.aaf7419","volume":"352","author":"GM Birchenough","year":"2016","unstructured":"Birchenough, G. M., Nystrom, E. E., Johansson, M. E. & Hansson, G. C. A sentinel goblet cell guards the colonic crypt by triggering Nlrp6-dependent Muc2 secretion. Science 352, 1535\u20131542 (2016).","journal-title":"Science"},{"key":"786_CR126","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.immuni.2019.02.006","volume":"50","author":"T Castro-Dopico","year":"2019","unstructured":"Castro-Dopico, T. et al. Anti-commensal IgG drives intestinal inflammation and Type 17 immunity in ulcerative colitis. Immunity 50, 1099\u20131114.e10 (2019).","journal-title":"Immunity"},{"key":"786_CR127","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.3390\/ijms18112409","volume":"18","author":"Y Qiu","year":"2017","unstructured":"Qiu, Y. et al. Lactobacillus plantarum enhanced IL-22 production in Natural Killer (NK) cells that protect the integrity of intestinal epithelial cell barrier damaged by enterotoxigenic Escherichia coli. Int J. Mol. Sci. 18, 2409 (2017).","journal-title":"Int J. Mol. Sci."},{"key":"786_CR128","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.immuni.2015.03.012","volume":"42","author":"X Guo","year":"2015","unstructured":"Guo, X. et al. Innate lymphoid cells control early colonization resistance against intestinal pathogens through ID2-dependent regulation of the microbiota. Immunity 42, 731\u2013743 (2015).","journal-title":"Immunity"},{"key":"786_CR129","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hep.32449","volume":"77","author":"C Hu","year":"2023","unstructured":"Hu, C. et al. Gut microbiota-derived short-chain fatty acids regulate group 3 innate lymphoid cells in HCC. Hepatology 77, 48\u201364 (2023).","journal-title":"Hepatology"},{"key":"786_CR130","doi-asserted-by":"crossref","unstructured":"Polonio, C. M. et al. 2025. The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation. Nat Rev Drug Discov (2025). Online ahead of print.","DOI":"10.1038\/s41573-025-01172-x"},{"key":"786_CR131","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nature24462","volume":"551","author":"VP Balachandran","year":"2017","unstructured":"Balachandran, V. P. et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551, 512\u2013516 (2017).","journal-title":"Nature"},{"key":"786_CR132","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1158\/1078-0432.CCR-21-1129","volume":"28","author":"D Davar","year":"2022","unstructured":"Davar, D. & Zarour, H. M. Facts and hopes for gut microbiota interventions in cancer immunotherapy. Clin. Cancer Res 28, 4370\u20134384 (2022). 2022.","journal-title":"Clin. Cancer Res"},{"key":"786_CR133","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41586-021-03368-8","volume":"592","author":"S Kalaora","year":"2021","unstructured":"Kalaora, S. et al. Identification of bacteria-derived HLA-bound peptides in melanoma. Nature 592, 138\u2013143 (2021).","journal-title":"Nature"},{"key":"786_CR134","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1182\/blood.2023021174","volume":"143","author":"JF Sanchez","year":"2024","unstructured":"Sanchez, J. F., Maknojia, A. A. & King, K. Y. Blood and guts: how the intestinal microbiome shapes hematopoiesis and treatment of hematologic disease. Blood 143, 1689\u20131701 (2024).","journal-title":"Blood"},{"key":"786_CR135","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1126\/science.1198469","volume":"331","author":"K Atarashi","year":"2011","unstructured":"Atarashi, K. et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331, 337\u2013341 (2011).","journal-title":"Science"},{"key":"786_CR136","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1126\/science.1206095","volume":"332","author":"JL Round","year":"2011","unstructured":"Round, J. L. et al. The toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 332, 974\u2013977 (2011).","journal-title":"Science"},{"key":"786_CR137","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12866-017-1044-0","volume":"17","author":"LJ Qian","year":"2017","unstructured":"Qian, L. J. et al. Early-life gut microbial colonization shapes Th1\/Th2 balance in asthma model in BALB\/c mice. BMC Microbiol. 17, 135 (2017).","journal-title":"BMC Microbiol."},{"key":"786_CR138","doi-asserted-by":"publisher","first-page":"26157","DOI":"10.1073\/pnas.1915978116","volume":"116","author":"D Erturk-Hasdemir","year":"2019","unstructured":"Erturk-Hasdemir, D. et al. Symbionts exploit complex signaling to educate the immune system. Proc. Natl. Acad. Sci. USA 116, 26157\u201326166 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"786_CR139","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s13238-020-00707-9","volume":"11","author":"Q Liu","year":"2020","unstructured":"Liu, Q., Sun, Z. & Chen, L. Memory T cells: strategies for optimizing tumor immunotherapy. Protein Cell 11, 549\u2013564 (2020).","journal-title":"Protein Cell"},{"key":"786_CR140","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-022-01273-9","volume":"15","author":"Y Lu","year":"2022","unstructured":"Lu, Y. et al. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. J. Hematol. Oncol. 15, 47 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"786_CR141","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.4049\/jimmunol.180.9.5843","volume":"180","author":"D Fujiwara","year":"2008","unstructured":"Fujiwara, D. et al. Systemic control of plasmacytoid dendritic cells by CD8+ T cells and commensal microbiota. J. Immunol. 180, 5843\u20135852 (2008).","journal-title":"J. Immunol."},{"key":"786_CR142","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.4049\/jimmunol.0902620","volume":"184","author":"B Wei","year":"2010","unstructured":"Wei, B. et al. Commensal microbiota and CD8+ T cells shape the formation of invariant NKT cells. J. Immunol. 184, 1218\u20131226 (2010).","journal-title":"J. Immunol."},{"key":"786_CR143","volume":"8","author":"R Zhu","year":"2021","unstructured":"Zhu, R. et al. Gut microbiota: influence on carcinogenesis and modulation strategies by drug delivery systems to improve cancer therapy. Adv. Sci. (Weinh.) 8, 2003542 (2021).","journal-title":"Adv. Sci. (Weinh.)"},{"key":"786_CR144","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s00262-024-03665-x","volume":"73","author":"B Pei","year":"2024","unstructured":"Pei, B., Peng, S., Huang, C. & Zhou, F. Bifidobacterium modulation of tumor immunotherapy and its mechanism. Cancer Immunol. Immunother. 73, 94 (2024).","journal-title":"Cancer Immunol. Immunother."},{"key":"786_CR145","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41579-020-0438-4","volume":"19","author":"KA Krautkramer","year":"2021","unstructured":"Krautkramer, K. A., Fan, J. & B\u00e4ckhed, F. Gut microbial metabolites as multi-kingdom intermediates. Nat. Rev. Microbiol. 19, 77\u201394 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"786_CR146","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/s41423-021-00661-4","volume":"18","author":"W Yang","year":"2021","unstructured":"Yang, W. & Cong, Y. Gut microbiota-derived metabolites in the regulation of host immune responses and immune-related inflammatory diseases. Cell Mol. Immunol. 18, 866\u2013877 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"786_CR147","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3390\/nu10081055","volume":"10","author":"T Zhang","year":"2018","unstructured":"Zhang, T., Yang, Y., Liang, Y., Jiao, X. & Zhao, C. Beneficial effect of intestinal fermentation of natural polysaccharides. Nutrients 10, 1055 (2018).","journal-title":"Nutrients"},{"key":"786_CR148","doi-asserted-by":"publisher","first-page":"13","DOI":"10.31083\/j.fbe1602013","volume":"16","author":"L Viretta","year":"2024","unstructured":"Viretta, L., Oldfield, D. & Sali, A. Inflammatory bowel diseases and the efficacy of probiotics as functional foods. Front Biosci. (Elite Ed.) 16, 13 (2024).","journal-title":"Front Biosci. (Elite Ed.)"},{"key":"786_CR149","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3892\/ijo.2024.5632","volume":"64","author":"J Sun","year":"2024","unstructured":"Sun, J. et al. Butyrate as a promising therapeutic target in cancer: From pathogenesis to clinic. Int J. Oncol. 64, 44 (2024).","journal-title":"Int J. Oncol."},{"key":"786_CR150","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s42255-022-00553-5","volume":"4","author":"AP Gomes","year":"2022","unstructured":"Gomes, A. P. et al. Altered propionate metabolism contributes to tumour progression and aggressiveness. Nat. Metab. 4, 435\u2013443 (2022).","journal-title":"Nat. Metab."},{"key":"786_CR151","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.cmet.2023.06.004","volume":"35","author":"C Xue","year":"2023","unstructured":"Xue, C. et al. Tryptophan metabolism in health and disease. Cell Metab. 35, 1304\u20131326 (2023).","journal-title":"Cell Metab."},{"key":"786_CR152","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/j.cell.2023.03.011","volume":"186","author":"MJ Bender","year":"2023","unstructured":"Bender, M. J. et al. Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell 186, 1846\u20131862.e26 (2023).","journal-title":"Cell"},{"key":"786_CR153","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.immuni.2022.01.006","volume":"55","author":"K Hezaveh","year":"2022","unstructured":"Hezaveh, K. et al. Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity. Immunity 55, 324\u2013340.e8 (2022).","journal-title":"Immunity"},{"key":"786_CR154","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33116-z","volume":"13","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. Inhibition of UBA6 by inosine augments tumour immunogenicity and responses. Nat. Commun. 13, 5413 (2022).","journal-title":"Nat. Commun."},{"key":"786_CR155","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1126\/science.abc3421","volume":"369","author":"LF Mager","year":"2020","unstructured":"Mager, L. F. et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science 369, 1481\u20131489 (2020).","journal-title":"Science"},{"key":"786_CR156","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cell.2013.11.042","volume":"156","author":"D An","year":"2014","unstructured":"An, D. et al. Sphingolipids from a symbiotic microbe regulate homeostasis of host intestinal natural killer T cells. Cell 156, 123\u2013133 (2014).","journal-title":"Cell"},{"key":"786_CR157","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrc.2017.96","volume":"18","author":"B Ogretmen","year":"2018","unstructured":"Ogretmen, B. Sphingolipid metabolism in cancer signalling and therapy. Nat. Rev. Cancer 18, 33\u201350 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"786_CR158","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/s12276-023-01018-9","volume":"55","author":"M Lee","year":"2023","unstructured":"Lee, M., Lee, S. Y. & Bae, Y. S. Functional roles of sphingolipids in immunity and their implication in disease. Exp. Mol. Med. 55, 1110\u20131130 (2023).","journal-title":"Exp. Mol. Med."},{"key":"786_CR159","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16274-w","volume":"11","author":"EL Johnson","year":"2020","unstructured":"Johnson, E. L. et al. Sphingolipids produced by gut bacteria enter host metabolic pathways impacting ceramide levels. Nat. Commun. 11, 2471 (2020).","journal-title":"Nat. Commun."},{"key":"786_CR160","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/j.celrep.2019.07.044","volume":"28","author":"P Chakraborty","year":"2019","unstructured":"Chakraborty, P. et al. Pro-Survival Lipid Sphingosine-1-Phosphate Metabolically Programs T Cells to Limit Anti-tumor Activity. Cell Rep. 28, 1879\u20131893.e7 (2019).","journal-title":"Cell Rep."},{"key":"786_CR161","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.3390\/ijms22031397","volume":"22","author":"N Gr\u00fcner","year":"2021","unstructured":"Gr\u00fcner, N. & Mattner, J. Bile Acids and Microbiota: Multifaceted and Versatile Regulators of the Liver-Gut Axis. Int J. Mol. Sci. 22, 1397 (2021).","journal-title":"Int J. Mol. Sci."},{"key":"786_CR162","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41586-022-04480-z","volume":"603","author":"D Paik","year":"2022","unstructured":"Paik, D. et al. Human gut bacteria produce TauEta17-modulating bile acid metabolites. Nature 603, 907\u2013912 (2022).","journal-title":"Nature"},{"key":"786_CR163","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.chom.2021.07.013","volume":"29","author":"W Li","year":"2021","unstructured":"Li, W. et al. A bacterial bile acid metabolite modulates Treg activity through the nuclear hormone receptor NR4A1. Cell Host Microbe 29, 1366\u20131377.e9 (2021).","journal-title":"Cell Host Microbe"},{"key":"786_CR164","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00018-022-04278-2","volume":"79","author":"T Re\u017een","year":"2022","unstructured":"Re\u017een, T. et al. The role of bile acids in carcinogenesis. Cell Mol. Life Sci. 79, 243 (2022).","journal-title":"Cell Mol. Life Sci."},{"key":"786_CR165","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.1263","volume":"12","author":"Q Yin","year":"2024","unstructured":"Yin, Q., Ni, J. J. & Ying, J. E. Potential mechanisms and targeting strategies of the gut microbiota in antitumor immunity and immunotherapy. Immun. Inflamm. Dis. 12, e1263 (2024).","journal-title":"Immun. Inflamm. Dis."},{"key":"786_CR166","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.202000426","volume":"64","author":"T Uebanso","year":"2020","unstructured":"Uebanso, T., Shimohata, T., Mawatari, K. & Takahashi, A. Functional Roles of B-Vitamins in the Gut and Gut Microbiome. Mol. Nutr. Food Res 64, e2000426 (2020).","journal-title":"Mol. Nutr. Food Res"},{"key":"786_CR167","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101718","volume":"5","author":"Y Yang","year":"2024","unstructured":"Yang, Y. et al. Dietary vitamin B3 supplementation induces the antitumor immunity against liver cancer via biased GPR109A signaling in myeloid cell. Cell Rep. Med. 5, 101718 (2024).","journal-title":"Cell Rep. Med."},{"key":"786_CR168","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.3390\/microorganisms10061168","volume":"10","author":"KS Hossain","year":"2022","unstructured":"Hossain, K. S., Amarasena, S. & Mayengbam, S. B Vitamins and Their Roles in Gut Health. Microorganisms 10, 1168 (2022).","journal-title":"Microorganisms"},{"key":"786_CR169","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1684\/bdc.2011.1458","volume":"98","author":"G Sujol","year":"2011","unstructured":"Sujol, G., Docquier, A., Boulahtouf, A., Castet-Nicolas, A. & Cavaill\u00e8s, V. Vitamin B6 and cancer: from clinical data to molecularly mechanisms. Bull. Cancer 98, 1201\u20131208 (2011).","journal-title":"Bull. Cancer"},{"key":"786_CR170","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.immuni.2016.09.009","volume":"45","author":"R Daillere","year":"2016","unstructured":"Daillere, R. et al. Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. Immunity 45, 931\u2013943 (2016).","journal-title":"Immunity"},{"key":"786_CR171","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1016\/j.cell.2021.09.019","volume":"184","author":"KC Lam","year":"2021","unstructured":"Lam, K. C. et al. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell 184, 5338\u201356.e21 (2021).","journal-title":"Cell"},{"key":"786_CR172","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s42255-020-0219-4","volume":"2","author":"T Wang","year":"2020","unstructured":"Wang, T. et al. Inosine is an alternative carbon source for CD8(+)-T-cell function under glucose restriction. Nat. Metab. 2, 635\u2013647 (2020).","journal-title":"Nat. Metab."},{"key":"786_CR173","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1126\/science.aax0701","volume":"369","author":"A Fluckiger","year":"2020","unstructured":"Fluckiger, A. et al. Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage. Science 369, 936\u2013942 (2020).","journal-title":"Science"},{"key":"786_CR174","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.135597","volume":"5","author":"CA Bessell","year":"2020","unstructured":"Bessell, C. A. et al. Commensal bacteria stimulate antitumor responses via T cell cross-reactivity. JCI insight 5, e135597 (2020).","journal-title":"JCI insight"},{"key":"786_CR175","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41586-023-06081-w","volume":"617","author":"R Naghavian","year":"2023","unstructured":"Naghavian, R. et al. Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma. Nature 617, 807\u2013817 (2023).","journal-title":"Nature"},{"key":"786_CR176","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16, 563\u2013580 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"786_CR177","doi-asserted-by":"publisher","first-page":"k793","DOI":"10.1136\/bmj.k793","volume":"360","author":"S Baxi","year":"2018","unstructured":"Baxi, S., Yang, A. & Gennarelli, R. L. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ 360, k793 (2018).","journal-title":"BMJ"},{"key":"786_CR178","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1007\/s13238-017-0400-z","volume":"8","author":"Z Wang","year":"2017","unstructured":"Wang, Z., Guo, Y. & Han, W. Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment. Protein Cell 8, 896\u2013925 (2017).","journal-title":"Protein Cell"},{"key":"786_CR179","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3390\/vaccines12080868","volume":"12","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. Intestinal microbiota and its effect on vaccine-induced immune amplification and tolerance. Vaccines (Basel) 12, 868 (2024).","journal-title":"Vaccines (Basel)"},{"key":"786_CR180","doi-asserted-by":"publisher","first-page":"1196625","DOI":"10.3389\/fnut.2023.1196625","volume":"10","author":"Y Zheng","year":"2023","unstructured":"Zheng, Y. et al. Effect of a probiotic formula on gastrointestinal health, immune responses and metabolic health in adults with functional constipation or functional diarrhea. Front. Nutr. 10, 1196625 (2023).","journal-title":"Front. Nutr."},{"key":"786_CR181","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00974-z","volume":"13","author":"M Usyk","year":"2021","unstructured":"Usyk, M. et al. Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma. Genome Med. 13, 160 (2021).","journal-title":"Genome Med."},{"key":"786_CR182","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1038\/s41591-018-0238-9","volume":"24","author":"Y Wang","year":"2018","unstructured":"Wang, Y. et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat. Med. 24, 1804\u20131808 (2018).","journal-title":"Nat. Med."},{"key":"786_CR183","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100464","volume":"2","author":"SJ Blake","year":"2021","unstructured":"Blake, S. J. et al. The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota. Cell Rep. Med. 2, 100464 (2021).","journal-title":"Cell Rep. Med."},{"key":"786_CR184","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","volume":"28","author":"N Chaput","year":"2017","unstructured":"Chaput, N. et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann. Oncol. 28, 1368\u20131379 (2017).","journal-title":"Ann. Oncol."},{"key":"786_CR185","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1126\/science.aay9189","volume":"368","author":"D Nejman","year":"2020","unstructured":"Nejman, D. et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science 368, 973\u2013980 (2020).","journal-title":"Science"},{"key":"786_CR186","doi-asserted-by":"crossref","unstructured":"Choi Y, et al. Immune checkpoint blockade induces gut microbiota translocation that augments extraintestinal antitumor immunity. Sci Immunol. 8, eabo2003 (2023).","DOI":"10.1126\/sciimmunol.abo2003"},{"key":"786_CR187","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.trecan.2023.03.005","volume":"9","author":"V Ferrari","year":"2023","unstructured":"Ferrari, V. & Rescigno, M. The intratumoral microbiota: friend or foe?. Trends Cancer 9, 472\u2013479 (2023).","journal-title":"Trends Cancer"},{"key":"786_CR188","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1389446","volume":"15","author":"J Xu","year":"2024","unstructured":"Xu, J. et al. Research progress on the impact of intratumoral microbiota on the immune microenvironment of malignant tumors and its role in immunotherapy. Front. Immunol. 15, 1389446 (2024).","journal-title":"Front. Immunol."},{"key":"786_CR189","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1158\/0008-5472.CAN-24-2580","volume":"85","author":"T Zhang","year":"2025","unstructured":"Zhang, T. et al. Intratumoral Fusobacterium nucleatum recruits tumor-associated neutrophils to promote gastric cancer progression and immune evasion. Cancer Res. 85, 1819\u20131841 (2025). 2025.","journal-title":"Cancer Res."},{"key":"786_CR190","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.immuni.2015.01.010","volume":"42","author":"C Gur","year":"2015","unstructured":"Gur, C. et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 42, 344\u2013355 (2015).","journal-title":"Immunity"},{"key":"786_CR191","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28913-5","volume":"13","author":"S Chen","year":"2022","unstructured":"Chen, S. et al. Fusobacterium nucleatum reduces METTL3-mediated m6A modification and contributes to colorectal cancer metastasis. Nat. Commun. 13, 1248 (2022).","journal-title":"Nat. Commun."},{"key":"786_CR192","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101488","volume":"5","author":"Y Ma","year":"2024","unstructured":"Ma, Y. et al. Intratumor microbiome-derived butyrate promotes lung cancer metastasis. Cell Rep. Med. 5, 101488 (2024).","journal-title":"Cell Rep. Med."},{"key":"786_CR193","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/cmi.2015.88","volume":"14","author":"BP Miao","year":"2017","unstructured":"Miao, B. P. et al. Inhibition of squamous cancer growth in a mouse model by Staphylococcal enterotoxin B-triggered Th9 cell expansion. Cell Mol. Immunol. 14, 371\u2013379 (2017).","journal-title":"Cell Mol. Immunol."},{"key":"786_CR194","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1038\/s41396-023-01483-0","volume":"17","author":"J Sun","year":"2023","unstructured":"Sun, J., Chen, F. & Wu, G. Potential effects of gut microbiota on host cancers: focus on immunity, DNA damage, cellular pathways, and anticancer therapy. ISME J. 17, 1535\u20131551 (2023).","journal-title":"ISME J."},{"key":"786_CR195","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar7785","volume":"363","author":"RM Wilson","year":"2019","unstructured":"Wilson, R. M. et al. The human gut bacterial genotoxin colibactin alkylates DNA. Science 363, eaar7785 (2019).","journal-title":"Science"},{"key":"786_CR196","doi-asserted-by":"publisher","first-page":"15354","DOI":"10.1073\/pnas.1010203108","volume":"108","author":"AC Goodwin","year":"2011","unstructured":"Goodwin, A. C. et al. Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proc. Natl Acad. Sci. USA 108, 15354\u201315359 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"786_CR197","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1126\/science.aah5043","volume":"357","author":"LT Geller","year":"2017","unstructured":"Geller, L. T. et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 357, 1156\u20131160 (2017).","journal-title":"Science"},{"key":"786_CR198","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.3390\/nu13041189","volume":"13","author":"M Wyatt","year":"2021","unstructured":"Wyatt, M. & Greathouse, K. L. Targeting Dietary and Microbial Tryptophan-Indole Metabolism as Therapeutic Approaches to Colon Cancer. Nutrients 13, 1189 (2021).","journal-title":"Nutrients"},{"key":"786_CR199","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1016\/j.immuni.2021.11.003","volume":"54","author":"AE Overacre-Delgoffe","year":"2021","unstructured":"Overacre-Delgoffe, A. E. et al. Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer. Immunity 54, 2812\u20132824.e4 (2021).","journal-title":"Immunity"},{"key":"786_CR200","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-022-01304-4","volume":"8","author":"L Yang","year":"2023","unstructured":"Yang, L., Li, A., Wang, Y. & Zhang, Y. Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy. Signal Transduct. Target Ther. 8, 35 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"786_CR201","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20192282","volume":"217","author":"Y Shi","year":"2020","unstructured":"Shi, Y. et al. Intra-tumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling. J. Exp. Med. 217, e20192282 (2020).","journal-title":"J. Exp. Med."},{"key":"786_CR202","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.autrev.2016.01.002","volume":"15","author":"M Dwivedi","year":"2016","unstructured":"Dwivedi, M., Kumar, P., Laddha, N. C. & Kemp, E. H. Induction of regulatory T cells: A role for probiotics and prebiotics to suppress autoimmunity. Autoimmun. Rev. 15, 379\u2013392 (2016).","journal-title":"Autoimmun. Rev."},{"key":"786_CR203","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg2697","volume":"9","author":"S Han","year":"2023","unstructured":"Han, S. et al. d-lactate modulates M2 tumor-associated macrophages and remodels immunosuppressive tumor microenvironment for hepatocellular carcinoma. Sci. Adv. 9, eadg2697 (2023).","journal-title":"Sci. Adv."},{"key":"786_CR204","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1146\/annurev-immunol-090222-102035","volume":"42","author":"T Takeuchi","year":"2024","unstructured":"Takeuchi, T., Nakanishi, Y. & Ohno, H. Microbial metabolites and gut immunology. Annu. Rev. Immunol. 42, 153\u2013178 (2024).","journal-title":"Annu. Rev. Immunol."},{"key":"786_CR205","doi-asserted-by":"publisher","first-page":"8434","DOI":"10.3390\/curroncol30090614","volume":"30","author":"E Domzaridou","year":"2023","unstructured":"Domzaridou, E. et al. The impact of oral antibiotics prior to cancer diagnosis on overall patient survival: findings from an english population-based cohort study. Curr. Oncol. 30, 8434\u20138443 (2023).","journal-title":"Curr. Oncol."},{"key":"786_CR206","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6267-z","volume":"19","author":"H Kim","year":"2019","unstructured":"Kim, H. et al. The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study. BMC Cancer 19, 1100 (2019).","journal-title":"BMC Cancer"},{"key":"786_CR207","doi-asserted-by":"publisher","first-page":"e1665973","DOI":"10.1080\/2162402X.2019.1665973","volume":"8","author":"XZ Huang","year":"2019","unstructured":"Huang, X. Z. et al. Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients. Oncoimmunology 8, e1665973 (2019).","journal-title":"Oncoimmunology"},{"key":"786_CR208","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00262-019-02453-2","volume":"69","author":"BE Wilson","year":"2020","unstructured":"Wilson, B. E. et al. The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies. Cancer Immunol. Immunother. 69, 343\u2013354 (2020).","journal-title":"Cancer Immunol. Immunother."},{"key":"786_CR209","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106876","volume":"88","author":"M Yang","year":"2020","unstructured":"Yang, M. et al. Antibiotic administration shortly before or after immunotherapy initiation is correlated with poor prognosis in solid cancer patients: an up-to-date systematic review and meta-analysis. Int. Immunopharmacol. 88, 106876 (2020).","journal-title":"Int. Immunopharmacol."},{"key":"786_CR210","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1846914","volume":"9","author":"PY Cren","year":"2020","unstructured":"Cren, P. Y. et al. Is the survival of patients treated with ipilimumab affected by antibiotics? An analysis of 1585 patients from the French National hospital discharge summary database (PMSI). Oncoimmunology 9, 1846914 (2020).","journal-title":"Oncoimmunology"},{"key":"786_CR211","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000803","volume":"5","author":"AA Kulkarni","year":"2020","unstructured":"Kulkarni, A. A. et al. Comparative analysis of antibiotic exposure association with clinical outcomes of chemotherapy versus immunotherapy across three tumour types. ESMO Open 5, e000803 (2020).","journal-title":"ESMO Open"},{"key":"786_CR212","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.euo.2019.09.001","volume":"3","author":"AA Lalani","year":"2020","unstructured":"Lalani, A. A. et al. Effect of antibiotic use on outcomes with systemic therapies in metastatic renal cell carcinoma. Eur. Urol. Oncol. 3, 372\u2013381 (2020).","journal-title":"Eur. Urol. Oncol."},{"key":"786_CR213","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1159\/000519108","volume":"10","author":"P Fessas","year":"2021","unstructured":"Fessas, P. et al. Early antibiotic exposure is not detrimental to therapeutic effect from immunotherapy in hepatocellular carcinoma. Liver Cancer 10, 583\u2013592 (2021).","journal-title":"Liver Cancer"},{"key":"786_CR214","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ejca.2021.08.036","volume":"157","author":"M Kostine","year":"2021","unstructured":"Kostine, M. et al. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. Eur. J. Cancer 157, 474\u2013484 (2021).","journal-title":"Eur. J. Cancer"},{"key":"786_CR215","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107303","volume":"92","author":"Q Wu","year":"2021","unstructured":"Wu, Q., Liu, J., Wu, S. & Xie, X. The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: a study based on 44 cohorts. Int Immunopharmacol. 92, 107303 (2021).","journal-title":"Int Immunopharmacol."},{"key":"786_CR216","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/jnci\/djaa057","volume":"113","author":"JJ Mohiuddin","year":"2021","unstructured":"Mohiuddin, J. J. et al. Association of antibiotic exposure with survival and toxicity in patients with melanoma receiving immunotherapy. J. Natl Cancer Inst. 113, 162\u2013170 (2021).","journal-title":"J. Natl Cancer Inst."},{"key":"786_CR217","doi-asserted-by":"publisher","first-page":"e003779","DOI":"10.1136\/jitc-2021-003779","volume":"10","author":"Y Jing","year":"2022","unstructured":"Jing, Y. et al. Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. J. Immunother. Cancer 10, e003779 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"786_CR218","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09210-2","volume":"22","author":"AF Nyein","year":"2022","unstructured":"Nyein, A. F. et al. Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer. BMC Cancer 22, 101 (2022).","journal-title":"BMC Cancer"},{"key":"786_CR219","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/CJI.0000000000000415","volume":"45","author":"L Zhao","year":"2022","unstructured":"Zhao, L. et al. Association of blood biochemical indexes and antibiotic exposure with severe immune-related adverse events in patients with advanced cancers receiving PD-1 inhibitors. J. Immunother. 45, 210\u2013216 (2022).","journal-title":"J. Immunother."},{"key":"786_CR220","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1093\/jnci\/djac019","volume":"114","author":"F Poizeau","year":"2022","unstructured":"Poizeau, F. et al. The association between antibiotic use and outcome among metastatic melanoma patients receiving immunotherapy. J. Natl Cancer Inst. 114, 686\u2013694 (2022).","journal-title":"J. Natl Cancer Inst."},{"key":"786_CR221","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.3390\/cancers15082342","volume":"15","author":"S Pressner","year":"2023","unstructured":"Pressner, S., Heiland, M., Preissner, R., Wirth, M. & Wollenberg, B. Antibiotics significantly decrease the survival of head and neck carcinoma patients with immunotherapy: a real-world analysis of more than 3000 cases. Cancers (Basel) 15, 2342 (2023).","journal-title":"Cancers (Basel)"},{"key":"786_CR222","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100747","volume":"5","author":"DJ Pinato","year":"2023","unstructured":"Pinato, D. J. et al. Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma. JHEP Rep. 5, 100747 (2023).","journal-title":"JHEP Rep."},{"key":"786_CR223","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00630-w","volume":"10","author":"AA Kulkarini","year":"2024","unstructured":"Kulkarini, A. A. et al. Association of antibiotic exposure with residual cancer burden in HER2-negative early stage breast cancer. NPJ Breast Cancer 10, 24 (2024).","journal-title":"NPJ Breast Cancer"},{"key":"786_CR224","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1158\/2159-8290.CD-24-0066","volume":"14","author":"IC Glitza","year":"2024","unstructured":"Glitza, I. C. et al. Randomized placebo-controlled, biomarker-stratified phase ib microbiome modulation in melanoma: impact of antibiotic preconditioning on microbiome and immunity. Cancer Discov. 14, 1161\u20131175 (2024).","journal-title":"Cancer Discov."},{"key":"786_CR225","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00630-w","volume":"8","author":"A Elkrief","year":"2024","unstructured":"Elkrief, A. et al. Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy. NPJ Precis Oncol. 8, 143 (2024).","journal-title":"NPJ Precis Oncol."},{"key":"786_CR226","doi-asserted-by":"crossref","unstructured":"Prasad, R. et al. Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy. Blood 145, 823\u2013839 (2024).","DOI":"10.1182\/blood.2024025366"},{"key":"786_CR227","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/ijc.35249","volume":"156","author":"K Takada","year":"2025","unstructured":"Takada, K., Takamori, S., Shimokawa, M., Pinato, D. & Cortellini, A. Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: a post-hoc analysis of the phase I\/III IMpower 133 trial. Int J. Cancer 156, 914\u2013919 (2025).","journal-title":"Int J. Cancer"},{"key":"786_CR228","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115223","volume":"217","author":"C Bonnefin","year":"2025","unstructured":"Bonnefin, C. et al. Antibiotics use decreases survival in cutaneous squamous cell carcinoma patients receiving immune checkpoint inhibitors. Eur. J. Cancer 217, 115223 (2025).","journal-title":"Eur. J. Cancer"},{"key":"786_CR229","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1158\/0008-5472.CAN-13-2462","volume":"74","author":"M Cheng","year":"2014","unstructured":"Cheng, M. et al. Microbiota modulate tumoral immune surveillance in lung through a \u03b3\u03b4T17 immune cell-dependent mechanism. Cancer Res. 74, 4030\u20134041 (2014).","journal-title":"Cancer Res."},{"key":"786_CR230","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","volume":"29","author":"Derosa","year":"2018","unstructured":"Derosa et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann. Oncol. 29, 1437\u20131444 (2018).","journal-title":"Ann. Oncol."},{"key":"786_CR231","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.annonc.2020.01.006","volume":"31","author":"M Chalabi","year":"2020","unstructured":"Chalabi, M. et al. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann. Oncol. 31, 525\u2013531 (2020).","journal-title":"Ann. Oncol."},{"key":"786_CR232","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1038\/s41564-018-0257-9","volume":"3","author":"A Palleja","year":"2018","unstructured":"Palleja, A. et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat. Microbiol. 3, 1255\u20131265 (2018).","journal-title":"Nat. Microbiol."},{"key":"786_CR233","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1507670","volume":"7","author":"J Ahmed","year":"2018","unstructured":"Ahmed, J. et al. Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors. Oncoimmunology 7, e1507670 (2018).","journal-title":"Oncoimmunology"},{"key":"786_CR234","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.chom.2022.02.004","volume":"30","author":"J Cai","year":"2022","unstructured":"Cai, J., Sun, L. & Gonzalez, F. J. Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis. Cell Host Microbe 30, 289\u2013300 (2022).","journal-title":"Cell Host Microbe"},{"key":"786_CR235","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1126\/science.abf8403","volume":"374","author":"N Pernigoni","year":"2021","unstructured":"Pernigoni, N. et al. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. Science 374, 216\u2013224 (2021).","journal-title":"Science"},{"key":"786_CR236","doi-asserted-by":"publisher","first-page":"e004191","DOI":"10.1136\/jitc-2021-004191","volume":"10","author":"S Terrisse","year":"2022","unstructured":"Terrisse, S. et al. Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer. J. Immunother. Cancer 10, e004191 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"786_CR237","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan8723","volume":"10","author":"M Rav\u00e0","year":"2018","unstructured":"Rav\u00e0, M. et al. Therapeutic synergy between tigecycline and venetoclax in a preclinical model of MYC\/BCL2 double-hit B cell lymphoma. Sci. Transl. Med. 10, eaan8723 (2018).","journal-title":"Sci. Transl. Med."},{"key":"786_CR238","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1158\/2159-8290.CD-17-1134","volume":"8","author":"S Pushalkar","year":"2018","unstructured":"Pushalkar, S. et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov. 8, 403\u2013416 (2018).","journal-title":"Cancer Discov."},{"key":"786_CR239","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1053\/j.gastro.2018.12.045","volume":"156","author":"V Sethi","year":"2019","unstructured":"Sethi, V., Vitiello, G. A., Saxena, D., Miller, G. & Dudeja, V. The role of the microbiome in immunologic development and its implication for pancreatic cancer immunotherapy. Gastroenterology 156, 2097\u20132115.e2 (2019).","journal-title":"Gastroenterology"},{"key":"786_CR240","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.trecan.2019.10.005","volume":"5","author":"GA Vitiello","year":"2019","unstructured":"Vitiello, G. A., Cohen, D. J. & Miller, G. Harnessing the microbiome for pancreatic cancer immunotherapy. Trends Cancer 5, 670\u2013676 (2019). 2019.","journal-title":"Trends Cancer"},{"key":"786_CR241","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ccell.2021.03.004","volume":"39","author":"A Bertocchi","year":"2021","unstructured":"Bertocchi, A. et al. Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. Cancer Cell 39, 708\u2013724.e11 (2021).","journal-title":"Cancer Cell"},{"key":"786_CR242","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3109\/00365548409087145","volume":"16","author":"A Schwan","year":"1984","unstructured":"Schwan, A., Sj\u00f6lin, S., Trottestam, U. & Aronsson, B. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand. J. Infect. Dis. 16, 211\u2013215 (1984).","journal-title":"Scand. J. Infect. Dis."},{"key":"786_CR243","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-030120","volume":"9","author":"N Pai","year":"2019","unstructured":"Pai, N., Popov, J., Hill, L. & Hartung, E. Protocol for a double-blind, randomised, placebo-controlled pilot study for assessing the feasibility and efficacy of faecal microbiota transplant in a paediatric Crohn\u2019s disease population: PediCRaFT Trial. BMJ Open 9, e030120 (2019).","journal-title":"BMJ Open"},{"key":"786_CR244","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/ NCT06218602 (Accessed 15 February 2025)."},{"key":"786_CR245","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03353402 (Accessed 15 February 2025)."},{"key":"786_CR246","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03772899 (Accessed 15 February 2025)."},{"key":"786_CR247","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05251389 (Accessed 15 February 2025)."},{"key":"786_CR248","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03341143 (Accessed 15 February 2025)."},{"key":"786_CR249","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04577729 (Accessed 15 February 2025)."},{"key":"786_CR250","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06623461 (Accessed 15 February 2025)."},{"key":"786_CR251","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04521075 (Accessed 15 February 2025)."},{"key":"786_CR252","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04951583 (Accessed 15 February 2025)."},{"key":"786_CR253","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05008861 (Accessed 15 February 2025)."},{"key":"786_CR254","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06403111 (Accessed 15 February 2025)."},{"key":"786_CR255","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05502913 (Accessed 15 February 2025)."},{"key":"786_CR256","unstructured":"US National Library of MediciAccessed 15ne. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04924374 (Accessed 15 February 2025)."},{"key":"786_CR257","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04056026 (Accessed 15 February 2025)."},{"key":"786_CR258","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06486220 (Accessed 15 February 2025)."},{"key":"786_CR259","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05750030 (Accessed 15 February 2025)."},{"key":"786_CR260","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05690048 Accessed 15 February 2025)."},{"key":"786_CR261","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06405113 (Accessed 15 February 2025)."},{"key":"786_CR262","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04130763 (Accessed 15 February 2025)."},{"key":"786_CR263","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04038619 (Accessed 15 February 2025)."},{"key":"786_CR264","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04729322 (Accessed 15 February 2025)."},{"key":"786_CR265","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05279677 (Accessed 15 February 2025)."},{"key":"786_CR266","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04163289 (Accessed 15 February 2025)."},{"key":"786_CR267","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04038619 (Accessed 15 February 2025)."},{"key":"786_CR268","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04758507 (Accessed 15 February 2025)."},{"key":"786_CR269","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04116775 (Accessed 15 February 2025)."},{"key":"786_CR270","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04883762 (Accessed 15 February 2025)."},{"key":"786_CR271","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04521075 (Accessed 15 February 2025)."},{"key":"786_CR272","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05286294 (Accessed 15 February 2025)."},{"key":"786_CR273","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03819296 (Accessed 15 February 2025)."},{"key":"786_CR274","unstructured":"Chinese Clinical Trial Register. https:\/\/www.chictr.org.cn\/historyversionpub.aspx?regno=ChiCTR2100042292 (Accessed 15 February 2025)."},{"key":"786_CR275","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05273255 (Accessed 15 February 2025)."},{"key":"786_CR276","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41586-020-2971-8","volume":"588","author":"J Schluter","year":"2020","unstructured":"Schluter, J. et al. The gut microbiota is associated with immune cell dynamics in humans. Nature 588, 303\u2013307 (2020).","journal-title":"Nature"},{"key":"786_CR277","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.678476","volume":"12","author":"Y Zhao","year":"2021","unstructured":"Zhao, Y. et al. Safety and efficacy of fecal microbiota transplantation for grade IV steroid refractory GI-GvHD patients: interim results from FMT2017002 trial. Front Immunol. 12, 678476 (2021).","journal-title":"Front Immunol."},{"key":"786_CR278","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq4006","volume":"15","author":"TM Halesy","year":"2023","unstructured":"Halesy, T. M. et al. Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis. Sci. Transl. Med. 15, eabq4006 (2023).","journal-title":"Sci. Transl. Med."},{"key":"786_CR279","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41591-019-0377-7","volume":"25","author":"BA Helmink","year":"2019","unstructured":"Helmink, B. A., Khan, M. A. W., Hermann, A., Gopalakrishnan, V. & Wargo, J. A. The microbiome, cancer, and cancer therapy. Nat. Med. 25, 377\u201388 (2019).","journal-title":"Nat. Med."},{"key":"786_CR280","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133410","volume":"4","author":"JS Bajaj","year":"2019","unstructured":"Bajaj, J. S. et al. Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis. JCI Insight 4, e133410 (2019).","journal-title":"JCI Insight"},{"key":"786_CR281","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18127-y","volume":"11","author":"G Ianiro","year":"2020","unstructured":"Ianiro, G. et al. Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma. Nat. Commun. 11, 4333 (2020).","journal-title":"Nat. Commun."},{"key":"786_CR282","doi-asserted-by":"publisher","first-page":"101076","DOI":"10.1016\/j.molmet.2020.101076","volume":"42","author":"AV Hartstra","year":"2020","unstructured":"Hartstra, A. V. et al. Infusion of donor feces affects the gut-brain axis in humans with metabolic syndrome. Mol. Metab. 42, 101076 (2020).","journal-title":"Mol. Metab."},{"key":"786_CR283","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1056\/NEJMoa1910437","volume":"381","author":"Z DeFilipp","year":"2019","unstructured":"DeFilipp, Z. et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N. Engl. J. Med. 381, 2043\u20132050 (2019).","journal-title":"N. Engl. J. Med."},{"key":"786_CR284","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S1473-3099(20)30473-4","volume":"21","author":"KEW Vendrik","year":"2021","unstructured":"Vendrik, K. E. W. et al. Periodic screening of donor faeces with a quarantine period to prevent transmission of multidrug-resistant organisms during faecal microbiota transplantation: a retrospective cohort study. Lancet Infect. Dis. 21, 711\u2013721 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"786_CR285","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/S0140-6736(12)62018-2","volume":"380","author":"SH Podolsky","year":"2012","unstructured":"Podolsky, S. H. Metchnikoff and the microbiome. Lancet 380, 1810\u20131811 (2012).","journal-title":"Lancet"},{"key":"786_CR286","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nrgastro.2014.66","volume":"11","author":"C Hill","year":"2014","unstructured":"Hill, C. et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 11, 506\u2013514 (2014).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"786_CR287","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.yexcr.2017.07.009","volume":"358","author":"Y Rong","year":"2017","unstructured":"Rong, Y. et al. Reactivity toward Bifidobacterium longum and Enterococcus hirae demonstrate robust CD8(\u2009+\u2009) T cell response and better prognosis in HBV-related hepatocellular carcinoma. Exp. Cell Res. 358, 352\u2013359 (2017).","journal-title":"Exp. Cell Res."},{"key":"786_CR288","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3390\/microorganisms8091395","volume":"8","author":"B Lee","year":"2020","unstructured":"Lee, B. et al. Modulation of the gut microbiota alters the tumour-suppressive efficacy of Tim-3 pathway blockade in a bacterial species- and host factor-dependent manner. Microorganisms 8, 1395 (2020).","journal-title":"Microorganisms"},{"key":"786_CR289","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56661-y","volume":"9","author":"Q Zhuo","year":"2019","unstructured":"Zhuo, Q. et al. Lysates of Lactobacillus acidophilus combined with CTLA-4-blocking antibodies enhance antitumor immunity in a mouse colon cancer model. Sci. Rep. 9, 20128 (2019).","journal-title":"Sci. Rep."},{"key":"786_CR290","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41564-020-00831-6","volume":"6","author":"SH Lee","year":"2021","unstructured":"Lee, S. H. et al. Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice. Nat. Microbiol. 6, 277\u2013288 (2021).","journal-title":"Nat. Microbiol."},{"key":"786_CR291","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1053\/j.gastro.2020.09.003","volume":"160","author":"Q Li","year":"2021","unstructured":"Li, Q. et al. Streptococcus thermophilus inhibits colorectal tumorigenesis through secreting beta-galactosidase. Gastroenterology 160, 1179\u20131193.e14 (2021).","journal-title":"Gastroenterology"},{"key":"786_CR292","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3390\/microorganisms9030618","volume":"9","author":"RA Corb Aron","year":"2021","unstructured":"Corb Aron, R. A. et al. Recognizing the benefits of pre-\/probiotics in metabolic syndrome and type 2 diabetes mellitus considering the influence of Akkermansia muciniphila as a key gut bacterium. Microorganisms 9, 618 (2021).","journal-title":"Microorganisms"},{"key":"786_CR293","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1126\/science.aaw7479","volume":"364","author":"E Ansaldo","year":"2019","unstructured":"Ansaldo, E. et al. Akkermansia muciniphila induces intestinal adaptive immune responses during homeostasis. Science 364, 1179\u20131184 (2019).","journal-title":"Science"},{"key":"786_CR294","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2019.1613124","volume":"11","author":"C Lordan","year":"2020","unstructured":"Lordan, C., Thapa, D., Ross, R. P. & Cotter, P. D. Potential for enriching next-generation health-promoting gut bacteria through prebiotics and other dietary components. Gut Microbes 11, 1\u201320 (2020).","journal-title":"Gut Microbes"},{"key":"786_CR295","doi-asserted-by":"publisher","first-page":"e000973","DOI":"10.1136\/jitc-2020-000973","volume":"8","author":"L Shi","year":"2020","unstructured":"Shi, L. et al. Combining IL-2-based immunotherapy with commensal probiotics produces enhanced anti-tumor immune response and tumor clearance. J. Immunother. Cancer 8, e000973 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"786_CR296","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41586-019-0878-z","volume":"565","author":"T Tanoue","year":"2019","unstructured":"Tanoue, T. et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature 565, 600\u2013605 (2019).","journal-title":"Nature"},{"key":"786_CR297","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.chom.2021.08.001","volume":"29","author":"A Montalban-Arques","year":"2021","unstructured":"Montalban-Arques, A. et al. Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors. Cell Host Microbe 29, 1573\u20131588.e7 (2021).","journal-title":"Cell Host Microbe"},{"key":"786_CR298","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nrc.2017.13","volume":"17","author":"S Roy","year":"2017","unstructured":"Roy, S. & Trichieri, G. Microbiota: a key orchestrator of cancer therapy. Nat. Rev. Cancer 17, 271\u2013285 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"786_CR299","doi-asserted-by":"publisher","first-page":"E14","DOI":"10.1016\/S1470-2045(18)30919-7","volume":"20","author":"M Das","year":"2019","unstructured":"Das, M. Probiotics for chemoradiotherapy-induced oral mucositis. Lancet Oncol. 20, E14 (2019).","journal-title":"Lancet Oncol."},{"key":"786_CR300","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/cncr.31907","volume":"125","author":"C Jiang","year":"2019","unstructured":"Jiang, C. et al. A randomized, double-blind, placebo-controlled trial of probiotics to reduce the severity of oral mucositis induced by chemoradiotherapy for patients with nasopharyngeal carcinoma. Cancer 125, 1081\u20131090 (2019).","journal-title":"Cancer"},{"key":"786_CR301","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1177\/0148607115584387","volume":"40","author":"ML Consoli","year":"2016","unstructured":"Consoli, M. L. et al. Randomized clinical trial: impact of oral administration of Saccharomyces boulardii on gene expression of intestinal cytokines in patients undergoing colon resection. JPEN J. Parenter. Enter. Nutr. 40, 1114\u20131121 (2016).","journal-title":"JPEN J. Parenter. Enter. Nutr."},{"key":"786_CR302","doi-asserted-by":"publisher","first-page":"e000145","DOI":"10.1136\/bmjgast-2017-000145","volume":"4","author":"AA Hibberd","year":"2017","unstructured":"Hibberd, A. A. et al. Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention. BMJ Open Gastroenterol. 4, e000145 (2017).","journal-title":"BMJ Open Gastroenterol."},{"key":"786_CR303","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04988841 (Accessed 15 February 2025)."},{"key":"786_CR304","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03595683 (Accessed 15 February 2025)."},{"key":"786_CR305","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04699721 (Accessed 15 February 2025)."},{"key":"786_CR306","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04909034 (Accessed 15 February 2025)."},{"key":"786_CR307","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05094167 (Accessed 15 February 2025)."},{"key":"786_CR308","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06428422 (Accessed 15 February 2025)."},{"key":"786_CR309","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06768931 (Accessed 15 February 2025)."},{"key":"786_CR310","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05032014 (Accessed 15 February 15, 2025)."},{"key":"786_CR311","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05122546 (Accessed 15 February 2025)."},{"key":"786_CR312","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05220124 (Accessed 15 February 2025)."},{"key":"786_CR313","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03686202 (Accessed 15 February 2025)."},{"key":"786_CR314","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03775850 (Accessed 15 February 2025)."},{"key":"786_CR315","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03637803 (Accessed 15 February 2025)."},{"key":"786_CR316","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04208958 (Accessed 15 February 2025)."},{"key":"786_CR317","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06508034 (Accessed 15 February 2025)."},{"key":"786_CR318","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-36926-8","volume":"9","author":"DL Laut\u00e9-Caly","year":"2019","unstructured":"Laut\u00e9-Caly, D. L. et al. The flagellin of candidate live biotherapeutic Enterococcus gallinarum MRx0518 is a potent immunostimulant. Sci. Rep. 9, 801 (2019).","journal-title":"Sci. Rep."},{"key":"786_CR319","unstructured":"Available online: https:\/\/www.biospace.com\/4d-pharma-announces-positive-interim-results-from-the-phase-i-ii-study-of-the-combination-of-mrx0518-and-keytruda-pembrolizumab-for-the-treatment-of-renal-cell-carcinoma (Accessed 15 February 2025)"},{"key":"786_CR320","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1158\/2326-6066.CIR-20-0051","volume":"8","author":"Y Tomita","year":"2020","unstructured":"Tomita, Y. et al. Association of probiotic Clostridium butyricum therapy with survival and response to immune checkpoint blockade in patients with lung cancer. Cancer Immunol. Res. 8, 1236\u20131242 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"786_CR321","doi-asserted-by":"publisher","first-page":"2081010","DOI":"10.1080\/2162402X.2022.2081010","volume":"11","author":"Y Tomita","year":"2022","unstructured":"Tomita, Y. et al. Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors. Oncoimmunology 11, 2081010 (2022).","journal-title":"Oncoimmunology"},{"key":"786_CR322","doi-asserted-by":"publisher","first-page":"S195","DOI":"10.1016\/j.annonc.2020.04.407","volume":"31","author":"D McHale","year":"2020","unstructured":"McHale, D. et al. Oral delivery of a single microbial strain, EDP1503, induces anti-tumor responses via gut-mediated activation of both innate and adaptive immunity. Ann. Oncol. 31, S195 (2020).","journal-title":"Ann. Oncol."},{"key":"786_CR323","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa2106516","volume":"386","author":"P Feuerstadt","year":"2022","unstructured":"Feuerstadt, P. et al. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N. Engl. J. Med. 386, 220\u2013229 (2022).","journal-title":"N. Engl. J. Med."},{"key":"786_CR324","doi-asserted-by":"publisher","first-page":"107978","DOI":"10.1016\/j.pharmthera.2021.107978","volume":"231","author":"S Snigdha","year":"2022","unstructured":"Snigdha, S. et al. Probiotics: Potential novel therapeutics for microbiota-gut-brain axis dysfunction across gender and lifespan. Pharm. Ther. 231, 107978 (2022).","journal-title":"Pharm. Ther."},{"key":"786_CR325","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2022","unstructured":"Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561\u2013565 (2022).","journal-title":"Nature"},{"key":"786_CR326","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/978-1-0716-4184-2_16","volume":"2864","author":"NH Ruddle","year":"2025","unstructured":"Ruddle, N. H. Tertiary Lymphoid Structures and Immunotherapy: Challenges and Opportunities. Methods Mol. Biol. 2864, 299\u2013312 (2025).","journal-title":"Methods Mol. Biol."},{"key":"786_CR327","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.chom.2014.11.010","volume":"17","author":"RN Carmody","year":"2015","unstructured":"Carmody, R. N. et al. Diet dominates host genotype in shaping the murine gut microbiota. Cell Host Microbe 17, 72\u201384 (2015).","journal-title":"Cell Host Microbe"},{"key":"786_CR328","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nature12506","volume":"500","author":"E Le Chatelier","year":"2013","unstructured":"Le Chatelier, E. et al. Richness of human gut microbiome correlates with metabolic markers. Nature 500, 541\u2013546 (2013).","journal-title":"Nature"},{"key":"786_CR329","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.1016\/j.cell.2021.06.019","volume":"184","author":"HC Wastyk","year":"2021","unstructured":"Wastyk, H. C. et al. Gut-microbiota-targeted diets modulate human immune status. Cell 184, 4137\u20134153.e14 (2021).","journal-title":"Cell"},{"key":"786_CR330","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17644-0","volume":"11","author":"A Buque","year":"2020","unstructured":"Buque, A. et al. Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Nat. Commun. 11, 3819 (2020).","journal-title":"Nat. Commun."},{"key":"786_CR331","doi-asserted-by":"publisher","first-page":"e145207","DOI":"10.1172\/jci.insight.145207","volume":"6","author":"G Ferrere","year":"2021","unstructured":"Ferrere, G. et al. Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. JCI Insight 6, e145207 (2021).","journal-title":"JCI Insight"},{"key":"786_CR332","doi-asserted-by":"publisher","first-page":"e1657375","DOI":"10.1080\/2162402X.2019.1657375","volume":"8","author":"S Levesque","year":"2019","unstructured":"Levesque, S. et al. A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice. Oncoimmunology 8, e1657375 (2019).","journal-title":"Oncoimmunology"},{"key":"786_CR333","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ccell.2016.05.016","volume":"30","author":"F Pietrocola","year":"2016","unstructured":"Pietrocola, F. et al. Caloric restriction mimetics enhance anticancer immunosurveillance. Cancer Cell 30, 147\u2013160 (2016).","journal-title":"Cancer Cell"},{"key":"786_CR334","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26431-4","volume":"12","author":"LCD Pomatto-Watson","year":"2021","unstructured":"Pomatto-Watson, L. C. D. et al. Daily caloric restriction limits tumor growth more effectively than caloric cycling regardless of dietary composition. Nat. Commun. 12, 6201 (2021).","journal-title":"Nat. Commun."},{"key":"786_CR335","doi-asserted-by":"publisher","first-page":"109516","DOI":"10.1016\/j.celrep.2021.109516","volume":"36","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. NAD+ supplement potentiates tumor-killing function by rescuing defective TUB-mediated NAMPT transcription in tumor-infiltrated T cells. Cell Rep. 36, 109516 (2021).","journal-title":"Cell Rep."},{"key":"786_CR336","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.cell.2019.07.049","volume":"178","author":"N Collins","year":"2019","unstructured":"Collins, N. et al. The bone marrow protects and optimizes immunological memory during dietary restriction. Cell 178, 1088\u20131101.e15 (2019).","journal-title":"Cell"},{"key":"786_CR337","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.cell.2016.10.043","volume":"167","author":"MS Desai","year":"2016","unstructured":"Desai, M. S. et al. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell 167, 1339\u20131353.e21 (2016).","journal-title":"Cell"},{"key":"786_CR338","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1016\/j.cmet.2024.10.019","volume":"36","author":"H Tong","year":"2024","unstructured":"Tong, H. et al. Dual impacts of serine\/glycine-free diet in enhancing antitumor immunity and promoting evasion via PD-L1 lactylation. Cell Metab. 36, 2493\u20132510.e9 (2024).","journal-title":"Cell Metab."},{"key":"786_CR339","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.cell.2016.05.041","volume":"165","author":"A Koh","year":"2016","unstructured":"Koh, A., De Vadder, F., Kovatcheva-Datchary, P. & B\u00e4ckhed, F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell 165, 1332\u20131345 (2016).","journal-title":"Cell"},{"key":"786_CR340","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/19490976.2015.1134082","volume":"7","author":"DJ Morrison","year":"2016","unstructured":"Morrison, D. J. & Preston, T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 7, 189\u2013200 (2016).","journal-title":"Gut Microbes"},{"key":"786_CR341","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16079-x","volume":"11","author":"C Coutzac","year":"2020","unstructured":"Coutzac, C. et al. Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. Nat. Commun. 11, 2168 (2020).","journal-title":"Nat. Commun."},{"key":"786_CR342","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41575-019-0173-3","volume":"16","author":"ME Sanders","year":"2019","unstructured":"Sanders, M. E., Merenstein, D. J., Reid, G., Gibson, G. R. & Rastall, R. A. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat. Rev. Gastroenterol. Hepatol. 16, 605\u2013616 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"786_CR343","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nrgastro.2017.75","volume":"14","author":"GR Gibson","year":"2017","unstructured":"Gibson, G. R. et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat. Rev. Gastroenterol. Hepatol. 14, 491\u2013502 (2017).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"786_CR344","doi-asserted-by":"publisher","first-page":"5707150","DOI":"10.1155\/2019\/5707150","volume":"2019","author":"Y Becerril-Alarcon","year":"2019","unstructured":"Becerril-Alarcon, Y. et al. Inulin supplementation reduces systolic blood pressure in women with breast cancer undergoing neoadjuvant chemotherapy. Cardiovasc Ther. 2019, 5707150 (2019).","journal-title":"Cardiovasc Ther."},{"key":"786_CR345","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/s12276-020-0449-2","volume":"52","author":"M Beukema","year":"2020","unstructured":"Beukema, M., Faas, M. M. & de Vos, P. The effects of different dietary fiber pectin structures on the gastrointestinal immune barrier: impact via gut microbiota and direct effects on immune cells. Exp. Mol. Med. 52, 1364\u20131376 (2020).","journal-title":"Exp. Mol. Med."},{"key":"786_CR346","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10096-019-03721-w","volume":"39","author":"Q Le Bastard","year":"2020","unstructured":"Le Bastard, Q. et al. The effects of inulin on gut microbial composition: a systematic review of evidence from human studies. Eur. J. Clin. Microbiol. Infect. Dis. 39, 403\u2013413 (2020).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"786_CR347","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-018-0483-7","volume":"6","author":"C Panebianco","year":"2018","unstructured":"Panebianco, C., Andriulli, A. & Pazienza, V. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies. Microbiome 6, 92 (2018).","journal-title":"Microbiome"},{"key":"786_CR348","doi-asserted-by":"publisher","first-page":"e2004529","DOI":"10.1002\/adma.202004529","volume":"32","author":"DW Zheng","year":"2020","unstructured":"Zheng, D. W. et al. Prebiotics-encapsulated probiotic spores regulate gut microbiota and suppress colon cancer. Adv. Mater. 32, e2004529 (2020).","journal-title":"Adv. Mater."},{"key":"786_CR349","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/s41551-021-00749-2","volume":"5","author":"K Han","year":"2021","unstructured":"Han, K. et al. Generation of systemic anti-tumour immunity via the in situ modulation of the gut microbiome by an orally administered inulin gel. Nat. Biomed. Eng. 5, 1377\u20131388 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"786_CR350","doi-asserted-by":"publisher","first-page":"4155","DOI":"10.7150\/thno.54476","volume":"11","author":"SL Zhang","year":"2021","unstructured":"Zhang, S. L. et al. Pectin supplement significantly enhanced the anti- PD-1 efficacy in tumor- bearing mice humanized with gut microbiota from patients with colorectal cancer. Theranostics 11, 4155\u20134170 (2021).","journal-title":"Theranostics"},{"key":"786_CR351","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1136\/gutjnl-2020-321031","volume":"71","author":"J Huang","year":"2022","unstructured":"Huang, J. et al. Ginseng polysaccharides alter the gut microbiota and kynurenine\/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1\/programmed cell death ligand 1 (anti-PD-1\/PD-L1) immunotherapy. Gut 71, 734\u2013745 (2022).","journal-title":"Gut"},{"key":"786_CR352","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1158\/2159-8290.CD-21-0808","volume":"12","author":"M Messaoudene","year":"2022","unstructured":"Messaoudene, M. et al. A natural polyphenol exerts antitumor activity and circumvents anti-PD-1 resistance through effects on the gut microbiota. Cancer Discov. 12, 1070\u20131087 (2022).","journal-title":"Cancer Discov."},{"key":"786_CR353","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06466434 (Accessed 15 February 2025)."},{"key":"786_CR354","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-13234-1","volume":"24","author":"S Faria","year":"2024","unstructured":"Faria, S. et al. Diet and Immune Effects Trial (DIET)- a randomized, double-blinded dietary intervention study in patients with melanoma receiving immunotherapy. BMC Cancer 24, 1493 (2024).","journal-title":"BMC Cancer"},{"key":"786_CR355","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06298734 (Accessed 15 February 2025)."},{"key":"786_CR356","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06236360 (Accessed 15 February 2025)."},{"key":"786_CR357","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04866810 (Accessed 15 February 2025)."},{"key":"786_CR358","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03709147 (Accessed 15 February 2025)."},{"key":"786_CR359","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03700437 (Accessed 15 February 2025)."},{"key":"786_CR360","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06671613 (Accessed 15 February 2025)."},{"key":"786_CR361","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05763992 (Accessed 15 February 2025)."},{"key":"786_CR362","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06610097 (Accessed 15 February 2025)."},{"key":"786_CR363","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05083416 (Accessed 15 February 2025)."},{"key":"786_CR364","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06391099 (Accessed 15 February 2025)."},{"key":"786_CR365","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05356182 (Accessed 15 February 2025)."},{"key":"786_CR366","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05832606 (Accessed 15 February 2025)."},{"key":"786_CR367","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06438588 (Accessed 15 February 2025)."},{"key":"786_CR368","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.canlet.2019.01.037","volume":"448","author":"K Liang","year":"2019","unstructured":"Liang, K. et al. Genetically engineered Salmonella typhimurium: recent advances in cancer therapy. Cancer Lett. 448, 168\u2013181 (2019).","journal-title":"Cancer Lett."},{"key":"786_CR369","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13567-020-00796-8","volume":"51","author":"Y Chang","year":"2020","unstructured":"Chang, Y. et al. Dihydromyricetin attenuates Escherichia coli lipopolysaccharide-induced ileum injury in chickens by inhibiting NLRP3 inflammasome and TLR4\/NF-\u03baB signalling pathway. Vet. Res. 51, 72 (2020).","journal-title":"Vet. Res."},{"key":"786_CR370","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/978-1-4939-3515-4_5","volume":"1409","author":"S Taniguchi","year":"2016","unstructured":"Taniguchi, S., Shimatani, Y. & Fujimori, M. Tumor-Targeting therapy using gene-engineered anaerobic-nonpathogenic Bifidobacterium longum. Methods Mol. Biol. 1409, 49\u201360 (2016).","journal-title":"Methods Mol. Biol."},{"key":"786_CR371","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1126\/science.add9667","volume":"378","author":"CR Gurbatri","year":"2022","unstructured":"Gurbatri, C. R., Arpaia, N. & Danino, T. Engineering bacteria as interactive cancer therapies. Science 378, 858\u2013864 (2022).","journal-title":"Science"},{"key":"786_CR372","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cell.2016.09.031","volume":"167","author":"R Geiger","year":"2016","unstructured":"Geiger, R. et al. L-Arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell 167, 829\u201342.e13 (2016).","journal-title":"Cell"},{"key":"786_CR373","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41586-021-04003-2","volume":"598","author":"FP Canale","year":"2021","unstructured":"Canale, F. P. et al. Metabolic modulation of tumours with engineered bacteria for immunotherapy. Nature 598, 662\u2013666 (2021).","journal-title":"Nature"},{"key":"786_CR374","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16602-0","volume":"11","author":"DS Leventhal","year":"2020","unstructured":"Leventhal, D. S. et al. Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. Nat. Commun. 11, 2739 (2020).","journal-title":"Nat. Commun."},{"key":"786_CR375","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41591-019-0498-z","volume":"25","author":"S Chowdhury","year":"2019","unstructured":"Chowdhury, S. et al. Programmable bacteria induce durable tumor regression and systemic antitumor immunity. Nat. Med 25, 1057\u20131063 (2019).","journal-title":"Nat. Med"},{"key":"786_CR376","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41586-024-08033-4","volume":"635","author":"A Redenti","year":"2024","unstructured":"Redenti, A. et al. Probiotic neoantigen delivery vectors for precision cancer immunotherapy. Nature 635, 453\u2013461 (2024).","journal-title":"Nature"},{"key":"786_CR377","doi-asserted-by":"crossref","unstructured":"Yang, S. et al. Non-pathogenic E. coli displaying decoy-resistant IL18 mutein boosts anti-tumor and CAR NK cell responses. Nat Biotechnol. (2024) Online ahead of print.","DOI":"10.1038\/s41587-024-02418-6"},{"key":"786_CR378","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.18632\/oncotarget.27536","volume":"11","author":"C Eng","year":"2020","unstructured":"Eng, C. et al. A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent\/recurrent loco-regional or metastatic anal cancer. Oncotarget 11, 1334\u20131343 (2020).","journal-title":"Oncotarget"},{"key":"786_CR379","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1080\/21645515.2021.1893036","volume":"17","author":"T Galicia-Carmona","year":"2021","unstructured":"Galicia-Carmona, T. et al. ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer. Hum. Vaccin. Immunother. 17, 2617\u20132625 (2021).","journal-title":"Hum. Vaccin. Immunother."},{"key":"786_CR380","doi-asserted-by":"publisher","first-page":"eaau6849","DOI":"10.1126\/sciadv.aau6849","volume":"5","author":"SH Pennington","year":"2019","unstructured":"Pennington, S. H. et al. Nonspecific effects of oral vaccination with live-attenuated Salmonella Typhi strain Ty21a. Sci. Adv. 5, eaau6849 (2019).","journal-title":"Sci. Adv."},{"key":"786_CR381","doi-asserted-by":"publisher","first-page":"e1265720","DOI":"10.1080\/2162402X.2016.1265720","volume":"6","author":"S Domingos-Pereira","year":"2017","unstructured":"Domingos-Pereira, S. et al. Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer. Oncoimmunology 6, e1265720 (2017).","journal-title":"Oncoimmunology"},{"key":"786_CR382","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41391-021-00402-8","volume":"25","author":"CG Drake","year":"2022","unstructured":"Drake, C. G. et al. Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 25, 219\u2013228 (2022).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"786_CR383","doi-asserted-by":"publisher","first-page":"e1303584","DOI":"10.1080\/2162402X.2017.1303584","volume":"7","author":"FH Schmitz-Winnenthal","year":"2018","unstructured":"Schmitz-Winnenthal, F. H. et al. A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer. Oncoimmunology 7, e1303584 (2018).","journal-title":"Oncoimmunology"},{"key":"786_CR384","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1126\/science.abp9563","volume":"380","author":"YE Chen","year":"2023","unstructured":"Chen, Y. E. et al. Engineered skin bacteria induce antitumor T cell responses against melanoma. Science 380, 203\u2013210 (2023).","journal-title":"Science"},{"key":"786_CR385","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58553-4","volume":"16","author":"R Preet","year":"2025","unstructured":"Preet, R. et al. Gut commensal Bifidobacterium-derived extracellular vesicles modulate the therapeutic effects of anti-PD-1 in lung cancer. Nat. Commun. 16, 3500 (2025).","journal-title":"Nat. Commun."},{"key":"786_CR386","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1021\/acsami.2c18244","volume":"15","author":"XZ Liu","year":"2023","unstructured":"Liu, X. Z. et al. Bioengineered Bacterial Membrane Vesicles with Multifunctional Nanoparticles as a Versatile Platform for Cancer Immunotherapy. ACS Appl. Mater. Interfaces 15, 3744\u20133759 (2023).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"786_CR387","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s10565-024-09897-y","volume":"40","author":"J Zhang","year":"2024","unstructured":"Zhang, J. et al. Antitumorigenic potential of Lactobacillus-derived extracellular vesicles: p53 succinylation and glycolytic reprogramming in intestinal epithelial cells via SIRT5 modulation. Cell Biol. Toxicol. 40, 66 (2024).","journal-title":"Cell Biol. Toxicol."},{"key":"786_CR388","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.chom.2019.05.001","volume":"25","author":"BB Hsu","year":"2019","unstructured":"Hsu, B. B. et al. Dynamic modulation of the gut microbiota and metabolome by bacteriophages in a mouse model. Cell Host Microbe 25, 803\u2013814.e5 (2019).","journal-title":"Cell Host Microbe"},{"key":"786_CR389","doi-asserted-by":"publisher","first-page":"e00019","DOI":"10.1128\/mBio.00019-20","volume":"11","author":"K Selle","year":"2020","unstructured":"Selle, K. et al. In vivo targeting of clostridioides difficile using phage-delivered CRISPR-Cas3 antimicrobials. mBio 11, e00019\u2013e00020 (2020).","journal-title":"mBio"},{"key":"786_CR390","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jconrel.2020.06.016","volume":"326","author":"PJ Voorhees","year":"2020","unstructured":"Voorhees, P. J., Cruz-Teran, C., Edelstein, J. & Lai, S. K. Challenges & opportunities for phage-based in situ microbiome engineering in the gut. J. Control Release 326, 106\u2013119 (2020).","journal-title":"J. Control Release"},{"key":"786_CR391","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41551-019-0423-2","volume":"3","author":"DW Zheng","year":"2019","unstructured":"Zheng, D. W. et al. Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy. Nat. Biomed. Eng. 3, 717\u2013728 (2019).","journal-title":"Nat. Biomed. Eng."},{"key":"786_CR392","first-page":"391","volume":"9","author":"T Cieplak","year":"2018","unstructured":"Cieplak, T., Soffer, N., Sulakvelidze, A. & Nielsen, D. S. A bacteriophage cocktail targeting Escherichia coli reduces E. coli in simulated gut conditions, while preserving a non-targeted representative commensal normal microbiota. Gut Microbes 9, 391\u2013399 (2018).","journal-title":"Gut Microbes"},{"key":"786_CR393","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2478\/acph-2020-0021","volume":"70","author":"K Lipska","year":"2020","unstructured":"Lipska, K., Gumieniczek, A. & Filip, A. A. Anticonvulsant valproic acid and other short-chain fatty acids as novel anticancer therapeutics: Possibilities and challenges. Acta Pharm. 70, 291\u2013301 (2020).","journal-title":"Acta Pharm."},{"key":"786_CR394","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/s41587-020-0549-5","volume":"38","author":"PB Chen","year":"2020","unstructured":"Chen, P. B. et al. Directed remodeling of the mouse gut microbiome inhibits the development of atherosclerosis. Nat. Biotechnol. 38, 1288\u20131297 (2020).","journal-title":"Nat. Biotechnol."},{"key":"786_CR395","first-page":"A1","volume":"10","author":"D Reardon","year":"2022","unstructured":"Reardon, D. et al. EO2401 microbiome derived therapeutic vaccine + nivolumab, with\/without standard continuous, or low-dose symptom directed, bevacizumab, in recurrent glioblastoma: phase 1\u20132 EOGBM1\u201318\/ROSALIE study. J. Immunother. Cancer 10, A1\u2013A1603 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"786_CR396","unstructured":"Available online: https:\/\/www.onclive.com\/view\/eo2401-plus-nivolumab-and-bevacizumab-shows-activity-in-progressive-recurrent-glioblastoma (Accessed 27 February 2025)"},{"key":"786_CR397","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s43556-025-00248-9","volume":"6","author":"S Zhang","year":"2025","unstructured":"Zhang, S. et al. Tumor microbiome: roles in tumor initiation, progression, and therapy. Mol. Biomed. 6, 9 (2025).","journal-title":"Mol. Biomed."},{"key":"786_CR398","doi-asserted-by":"publisher","first-page":"101487","DOI":"10.1016\/j.xcrm.2024.101487","volume":"5","author":"Y Yousefi","year":"2024","unstructured":"Yousefi, Y., Baines, K. J. & Maleki Vareki, S. Microbiome bacterial influencers of host immunity and response to immunotherapy. Cell Rep. Med 5, 101487 (2024).","journal-title":"Cell Rep. Med"},{"key":"786_CR399","doi-asserted-by":"publisher","first-page":"7061","DOI":"10.3390\/ijms21197061","volume":"21","author":"DM Mrochen","year":"2020","unstructured":"Mrochen, D. M. et al. Staphylococcus aureus host tropism and its implications for murine infection models. Int J. Mol. Sci. 21, 7061 (2020).","journal-title":"Int J. Mol. Sci."},{"key":"786_CR400","doi-asserted-by":"publisher","first-page":"898615","DOI":"10.3389\/fimmu.2022.898615","volume":"13","author":"U Christen","year":"2022","unstructured":"Christen, U. & Hintermann, E. Animal models for autoimmune hepatitis: are current models good enough?. Front Immunol. 13, 898615 (2022).","journal-title":"Front Immunol."},{"key":"786_CR401","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1136\/gutjnl-2018-316723","volume":"67","author":"PD Cani","year":"2018","unstructured":"Cani, P. D. Human gut microbiome: hopes, threats and promises. Gut 67, 1716\u20131725 (2018).","journal-title":"Gut"},{"key":"786_CR402","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12866-017-1101-8","volume":"17","author":"I Allali","year":"2017","unstructured":"Allali, I. et al. A comparison of sequencing platforms and bioinformatics pipelines for compositional analysis of the gut microbiome. BMC Microbiol. 17, 194 (2017).","journal-title":"BMC Microbiol."},{"key":"786_CR403","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1101\/gr.151803.112","volume":"23","author":"CA Lozupone","year":"2013","unstructured":"Lozupone, C. A. et al. Meta-analyses of studies of the human microbiota. Genome Res. 23, 1704\u20131714 (2013).","journal-title":"Genome Res."},{"key":"786_CR404","unstructured":"Available online: https:\/\/asm.org\/articles\/2024\/february\/fecal-microbiota-transplants-past-present-future (Accessed 27 February 2025)"},{"key":"786_CR405","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-020-00923-9","volume":"8","author":"F Xu","year":"2020","unstructured":"Xu, F. et al. The interplay between host genetics and the gut microbiome reveals common and distinct microbiome features for complex human diseases. Microbiome 8, 145 (2020).","journal-title":"Microbiome"},{"key":"786_CR406","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41588-021-00991-z","volume":"54","author":"Y Qin","year":"2022","unstructured":"Qin, Y. et al. Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort. Nat. Genet. 54, 134\u2013142 (2022).","journal-title":"Nat. Genet."},{"key":"786_CR407","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/s41591-022-01964-3","volume":"28","author":"G Ianiro","year":"2022","unstructured":"Ianiro, G. et al. Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases. Nat. Med 28, 1913\u20131923 (2022).","journal-title":"Nat. Med"},{"key":"786_CR408","doi-asserted-by":"publisher","first-page":"863","DOI":"10.6004\/jnccn.2017.0127","volume":"15","author":"S Kato","year":"2017","unstructured":"Kato, S., Subbiah, V. & Kurzrock, R. Counterpoint: successes in the pursuit of precision medicine: biomarkers take credit. J. Natl Compr. Canc Netw. 15, 863\u2013866 (2017).","journal-title":"J. Natl Compr. Canc Netw."},{"key":"786_CR409","doi-asserted-by":"publisher","first-page":"100087","DOI":"10.1016\/j.bdq.2019.100087","volume":"17","author":"AJ Bronkhorst","year":"2019","unstructured":"Bronkhorst, A. J., Ungerer, V. & Holdenrieder, S. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol. Detect Quantif. 17, 100087 (2019).","journal-title":"Biomol. Detect Quantif."},{"key":"786_CR410","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1136\/gutjnl-2023-329614","volume":"73","author":"M Rehan","year":"2023","unstructured":"Rehan, M. et al. Smart capsules for sensing and sampling the gut: status, challenges and prospects. Gut 73, 186\u2013202 (2023).","journal-title":"Gut"},{"key":"786_CR411","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41378-023-00640-x","volume":"10","author":"M Lucchetti","year":"2024","unstructured":"Lucchetti, M. et al. Integration of multiple flexible electrodes for real-time detection of barrier formation with spatial resolution in a gut-on-chip system. Microsyst. Nanoeng. 10, 18 (2024).","journal-title":"Microsyst. Nanoeng."},{"key":"786_CR412","doi-asserted-by":"publisher","first-page":"e787","DOI":"10.1016\/S2666-5247(22)00185-9","volume":"3","author":"A Jordan","year":"2022","unstructured":"Jordan, A., Carding, S. R. & Hall, L. J. The early-life gut microbiome and vaccine efficacy. Lancet Microbe 3, e787\u2013e794 (2022).","journal-title":"Lancet Microbe"},{"key":"786_CR413","doi-asserted-by":"publisher","first-page":"1195075","DOI":"10.3389\/fimmu.2023.1195075","volume":"14","author":"N Jing","year":"2023","unstructured":"Jing, N. et al. Enhancing therapeutic effects of murine cancer vaccine by reshaping gut microbiota with Lactobacillus rhamnosus GG and jujube powder. Front. Immunol. 14, 1195075 (2023).","journal-title":"Front. Immunol."},{"key":"786_CR414","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.chom.2020.06.014","volume":"28","author":"SE de Jong","year":"2020","unstructured":"de Jong, S. E., Olin, A. & Pulendran, B. The impact of the microbiome on immunity to vaccination in humans. Cell Host Microbe 28, 169\u2013179 (2020).","journal-title":"Cell Host Microbe"},{"key":"786_CR415","doi-asserted-by":"publisher","first-page":"16","DOI":"10.15430\/JCP.2022.27.1.16","volume":"27","author":"R Issrani","year":"2022","unstructured":"Issrani, R., Reddy, J., Dabah, T. H. E. M. & Prabhu, N. Role of oral microbiota in carcinogenesis: a short review. J. Cancer Prev. 27, 16\u201321 (2022).","journal-title":"J. Cancer Prev."},{"key":"786_CR416","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/molecules26010206","volume":"26","author":"H Choudhry","year":"2021","unstructured":"Choudhry, H. The microbiome and its implications in cancer immunotherapy. Molecules 26, 206 (2021).","journal-title":"Molecules"},{"key":"786_CR417","doi-asserted-by":"publisher","first-page":"e100007","DOI":"10.1136\/egastro-2023-100007","volume":"1","author":"HCH Lau","year":"2023","unstructured":"Lau, H. C. H., Zhang, X. & Yu, J. Gut microbiota and immune alteration in cancer development: implication for immunotherapy. eGastroenterology 1, e100007 (2023).","journal-title":"eGastroenterology"}],"container-title":["npj Biofilms and Microbiomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41522-025-00786-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41522-025-00786-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41522-025-00786-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:56:53Z","timestamp":1757293013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41522-025-00786-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":417,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["786"],"URL":"https:\/\/doi.org\/10.1038\/s41522-025-00786-8","relation":{},"ISSN":["2055-5008"],"issn-type":[{"value":"2055-5008","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}